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ABSTRACT
Duchenne muscular dystrophy (DMD) is an x-linked lethal progressive disorder affecting
boys who are typically diagnosed due to motor delays or weakness. Key features include loss of
motor function throughout the lifetime resulting in early mortality from cardiopulmonary
complications in the late 2nd and 3rd decades of life. Rates of progression are variable yet
sequential due to a typical pattern of motor weakness that occurs from proximal to distal muscle
groups. Current standards of care include contracture management and Glucocorticosteroids
(GC). Timed function tests have been used to understand and predict loss of functional
milestones such as walking, getting off the ground and going upstairs. This study will describe
contracture development; associated strength loss and its effect on function for boys with DMD.
With differing rates of decline in boys with DMD, this study will also determine minimal clinical
important difference (MCID) based on annual progression rates of 3 critical timed function tests
(supine to stand, climb 4 stairs and 10meter walk test).
This is a retrospective study of the largest natural history of 440 boys with DMD. Data
was collected by physical therapists in a standardized manner across 22 sites in 9 countries.
Mixed models with repeated measures were used to understand the relationship between knee
strength, ankle range of motion, GC use and timed function tests. Linear regressions were used to
assess the effect of ankle range of motion and strength measures on functional ability. Anchor
based MCID measures were calculated based on change of the Vignos scale, an 8 point lower
extremity functional scale.
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Results found that there is great variability in contracture development in boys with
DMD and that a 12-month time frame may be too short to assess contracture changes. Knee
strength and ankle ROM are good predictors of loss of function. In an anticipatory care model,
MCID values for these functional tests are important in clinical management and necessary for
design of clinical trials.
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CHAPTER 1
INTRODUCTION
The most common form of pediatric muscular dystrophy is Duchenne muscular dystrophy
(DMD), caused by a genetic mutation in the dystrophin gene that leads to progressive muscle
weakness and loss of ambulation. The discovery of this gene over 30 years ago led to improved
diagnostic capabilities for DMD. Improved physical therapy management strategies and
therapeutic interventions have resulted in a longer lifespan and as a result increased variability in
rates of disease progression. Individuals with DMD have a chronic progressive loss of strength
and function, resulting in loss of ambulation in the teenage years and premature mortality
typically in the second or third decade of life.
Currently, standard of care guidelines for DMD emphasize appropriate musculoskeletal
management through physical therapy and corticosteroid therapy to maintain strength and
function. Obtaining a better understanding of how assessments used to measure impairments,
such as strength and range of motion (ROM), can be used in the clinic to predict disease
progression is important to achieve optimal, individualized rehabilitation management.
Predictive factors such as walking speed are associated with the loss of major functional
milestones including the ability to get off the ground, climb stairs and walk. This information is
vital to anticipatory care for rehabilitation specialists so that treatment recommendations can be
appropriately modified for contracture management. This information can also help rehab
professionals recommend equipment to ease the transition from losing such crucial functional
1

milestones like walking. In addition, understanding loss of functional milestones can be crucial
when designing a clinical trial in order to obtain the appropriate efficacy endpoint, study
population, and timeline.
Physical therapy is an essential component of care for individuals with DMD because of
the direct involvement of skeletal muscles in the disease process, and the secondary effects
associated with loss of joint ROM. The purpose of this research proposal is to better understand
the contribution of impairments, such as strength and ROM, to losses of functional abilities
including the ability to walk, get off the floor, and climb stairs.
For this project, the researcher performed a retrospective review of the largest
longitudinal natural history study of individuals with DMD. This study was performed by
Cooperative International Neuromuscular Research Group (CINRG), a consortium of 26 clinical
sites around the world with a primary goal of characterizing and understanding the
pathophysiology and clinical presentation of neuromuscular diseases and contributing to
improved clinical outcomes that are relevant to daily functional activities and quality of life
(www.Cinrgresearch.org). Data analysis determined the relationship between strength and ankle
range of motion and ability to perform functional activities including walk, climb stairs and get
up off of the floor in individuals with DMD. Minimal Clinically Important Differences (MCID)
was evaluated using an anchor-based approach that was anchored to an ordinal scale that
describes lower extremity functional changes, Vignos Scale.1 MCID for walking, climbing stairs,
and getting up off the floor was calculated by evaluating 12 month change scores of 3 timed
functional tests anchored to a change of levels on the Vignos scale.
2

The results of this study evaluated the relationship between musculoskeletal joint and
strength changes and performance on functional tests for individuals with DMD. Determining
MCID provided clinical thresholds for loss of function. This information will help physical
therapists better understand the potential effects of impairments on activity limitations and may
help to drive clinical decision making in selecting procedural interventions in boys with DMD.
In addition, this information will assist individuals and families in preparing for changes that
occur throughout the progression of the disease. As therapeutic trials have drastically increased
in the last decade, this predictive information will also help the researchers design better clinical
trials focused on a targeted population of individuals with DMD.
BACKGROUND AND PROBLEM STATEMENT
Duchenne muscular dystrophy (DMD) is a progressive genetic neuromuscular disease with a
prevalence of in every 7250 males from ages 5-24 years.2, 3 It is an X -linked developmental
disorder that causes progressive muscle weakness, usually leading to death by early adulthood.
Individuals with DMD battle many musculoskeletal challenges, including progressive muscle
weakness and development of contractures. Dystrophin deficiency is the primary defect in DMD,
resulting in a fragile muscle membrane that permits an abnormal permeability to electrolytes,
especially Ca++ 4. The increase in intracellular calcium triggers a pathological cascade of events
that results in downstream effects of muscle necrosis and fibrosis, which impede normal muscle
regeneration. Disease severity has not been directly related to amount of dystrophin in the
muscle. This dystrophin deficiency leads to downstream effects of muscle fibrosis and weakness
that lead to loss of function and development of contractures.5, 6
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Due to the intrinsic instability in the muscle membrane, individuals with DMD are at high
risk for formation of contractures.7-10 Contracture is defined as a lack of full passive range of
motion due to soft tissue, joint, or muscle strength imbalances in opposing muscle groups.9, 11
Fibrosis in combination with weakness result in loss of sarcomeres, which causes shortening of
muscle fibers and may contribute to development of contractures at the hip, knee, ankle, and
fingers.8 Additionally, this combination of progressive weakness and continued fibrosis results in
changes in muscle length that alter biomechanics of movement, especially during ambulation.1214

These changes in musculoskeletal alignment affect muscle force demands and result in

decreased gait velocity and associated loss of ambulation in boys with DMD.15-18
CLINICAL PRESENTATION
Many children show early signs of motor delays before the actual diagnosis of DMD. Due to
early pelvic girdle weakness, individuals typically have difficulty rising from the floor and will
use a classic compensatory movement strategy called Gower’s maneuver to get up from the
ground..19This maneuver is comprised of children using their hands to crawl up their legs in
order to get up from the ground. Children will also have difficulty obtaining some gross motor
milestones such as jumping or reciprocal stair climbing and may experience frequent falls. Over
the years, muscle imbalances lead to the development of contractures, scoliosis, and progressive
impairments of respiratory and cardiac capacity.5, 8 Phenotypical20 progression is variable in
DMD, but occurs in a predictable sequential manner. Individuals with DMD first lose the ability
to get off of the floor, then climb stairs, walk, feed oneself, and eventually a premature death
typically due to cardiorespiratory insufficiency.5, 6, 8, 13, 14, 21, 22
4

CURRENT THERAPIES
Corticosteroids, aggressive stretching/bracing, and physical therapy have effectively changed
the clinical course of the disease for most individuals with DMD.3, 6, 14, 21-36 Of all
neuromuscular disorders, DMD results in the greatest annual per capita cost for outpatient
rehabilitative treatment.20 Therapy goals focus on prevention of contractures and countering the
effects of deconditioning, along with maintenance of musculoskeletal health with range of
motion and weight bearing activities. For best utilization of rehabilitation interventions, an
evidence-based plan of care for DMD is necessary to understand the interplay between body
systems and disease progression.
With progression of the disease, therapy goals focus on addressing muscle imbalances
around joints to maintain optimal biomechanics for movement. Muscle weakness is initially seen
in the hip flexor, hip extensor, and knee extensor muscles resulting in functional changes.
However, contractures typically develop first at ankle plantarflexors, followed by hip flexors,
then iliotibial bands, and then forearm/finger contractures8. Significant contractures are rare in
children younger than 9 years and tend to develop more aggressively as individuals lose the
ability to stand or walk.8 This supports the theory that contracture development is multifactorial;
and has physiological and environmental components. Due to the high rate of fibrosis in DMD,
muscles with poor anti-gravity strength which persist in a shortened position will develop
contractures.5, 8-11The muscle imbalance between hip extensor weakness and hip flexor
contractures causes a pelvic anterior tilt resulting in a compensatory lumbar hyperlordosis.
Increased plantarflexion along with increased lumbar lordosis are a stabilizing mechanism to
shift the line of gravity behind the greater trochanter (posterior to the hip) and anterior to the
5

knee, in an effort to sustain a lower extremity extension moment. These compensations actually
lead to greater gait deficits including excessive plantarflexion, increased lateral trunk flexion,
circumduction, and a wide base of support.
With corticosteroid use, the time to when young boys lose ambulation has increased by 12 years, however, loss is still inevitable between the ages 9-15.37 Having at least a neutral (0
degrees) ankle range of motion (ROM) allows for better vertical alignment of the body’s center
of gravity in standing as well as foot clearance through the swing phase of ambulation. Older
studies representing a steroid naïve population have provided insight on associations with
functional abilities and ankle contractures/lower extremity strength deficits. A combination of
strong knee extensors and approximately normal ankle ROM has been shown to prolong
ambulation and positively affect the ability to get off the ground and climb stairs. 5, 12 Walking
speed in boys with DMD is directly correlated with prolonging ambulation, with individuals who
walked faster maintaining ambulation longer.8 There have been numerous studies linking
ambulation to improved quality of life and prevention of the development of scoliosis and joint
contractures/deformities.7, 8, 13 Once an individual becomes non-ambulatory, secondary issues
occur such as development of scoliosis, osteoporosis, obesity, disuse atrophy, increased rate of
contracture development, and psychosocial issues which impact the perception of disease
progression. The psychological effects of loss of a function are similar to the fears and anxiety
that is associated with loss felt at the time of diagnosis and death for families affected by DMD.38
Standards of care play a role in some of the variability in clinical progression. A study
investigating how DMD genetic factors were associated with loss of ambulation, found that SOC
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were a significant factor in differences in clinical progression.37 Additionally, findings from the
2005 Centers for Disease Control (CDC) expert panel indicate that SOC greatly varied based on
geographical location. Identifying and optimally managing secondary conditions in a
comprehensive and consistent manner is key for quality care.21, 25 Some of the discrepancies in
care include use of corticosteroid steroids and contracture management. The CDC determined
that stretching is the standard of care for management of contractures in boys with DMD, with
further recommendations for future research to validate expert consensus statements on bracing
and orthosis.25 However, there is inconsistency in the application of night time braces for
management of ankle contractures. Some of the inconsistencies in contracture management may
also be attributed to the lack of quality evidence to promote stretching or bracing as effective
means to manage contractures in individuals with neuromuscular disease (NMD). More recently,
a 2010 Cochrane review of interventions to increase ankle range of motion in neuromuscular
diseases concluded that the quality of evidence for interventions to increase ankle range of
motion was low and further research is required.10
SIGNIFICANCE
At a 2006 National Institute on Disability and Rehabilitation Research (NIDRR) meeting to
discuss challenges in muscle disease, the United States Food and Drug Administration (FDA)
specified that clinical trials conducted in support of new drug approvals or revised indications for
already approved drugs must incorporate a primary endpoint that objectively measures a
clinically meaningful “life-changing” milestone that has a significant impact on a patient’s
perceived overall health and well-being.31 In DMD, these milestones are likely to include events
such as loss of ability to rise from the floor and loss of ambulation. McDonald et al first showed
7

significant correlations of the Pediatric Outcomes Data Collection Instrument (PODCI) and the
Pediatric Quality of Life Inventory (PEDSQL) with age and timed functional tests in boys with
DMD.39This study was pivotal in proving construct validity of a parent reported health related
quality of life measure.39 The study team found that the PODCI domains of mobility/transfers
and sports/physical function best correlated to age, knee strength and timed tests.39 Even though
not explored in the McDonald40 study, contractures may play a significant role in the ability to
accomplish these “life changing” milestones, as the interactions of muscle force production and
the biomechanical demands may change based on the alignment of the musculoskeletal system
and progressive strength loss.
PURPOSE
The objective of this retrospective study is to explore the relationship of joint contractures
and muscle weakness to 3 timed functional test scores: supine to stand,10MWT, 4 stair climb. To
achieve this objective, the researcher will explore relationship between knee strength and ankle
range of motion on timed function tests (10MWT, Supine to stand, 4 stair climb) in ambulatory
boys. In addition, the MCID and minimal detectable change (MDC) on the 10-meter walk test,
supine to floor test, and stair climb test will be estimated for boys with DMD.
This CINRG study followed 440 boys aged 1-28 years for up to 10 years from the ages of 228 for 8 years. Data collected in this study includes a long list of clinical outcomes developed
based on the World Health Organization’s (WHO) International Classification of Function and
Disability (ICF) model.41 Data collected in this study ranges from basic anthropometric
measurements (height, weight, range of motion, limb measures) to functional assessments
8

(strength, gait velocity, stand from floor, stairs, Northstar Ambulatory Assessment (NSAA)),
quality of life PODCI, PedsQL, Short Form Health Survey (SF36), Neuro Quality of Life
Measure (NeuroQOL) measures, and surveys on access and use of interventions by the DMD
community.
Published work during the pre-steroid era by McDonald et al (1995) associated age ranges
with 4 distinct disease stages of DMD (< 6 years; 6 to <9 years; 9 to <12 years; > 12 years).
Since that time, the CDC care guidelines have described DMD in 5 stages based on function.
These include 1) diagnosis; 2) early Ambulatory; 3) late ambulatory; 4) early non- ambulatory;
5) late non-ambulatory. Of the 5 groups, major changes in clinical care recommendations for
cardiac, respiratory and gastrointestinal care were considered in 3 primary groups: early
(ambulatory); middle (early non-ambulatory); and late (late stage ambulatory). Because this
project is exploring rehabilitation, physical therapy, and orthopedic clinical care considerations
with recommendations based on the 5 age groupings,5, 21, 22, 42, 43 the researcher performed data
analysis based on 5 distinct functional groups based on age. These groups were defined as
diagnosis (0-4 years); early Ambulatory (5-8.9 years); late ambulatory (9-12.9 years); early nonambulatory (13-16 years); and late non-ambulatory (>17years). This 5-tier stratification based
on loss of function describes distinct phases where significant changes in care may occur.
Estimates of MCID of functional timed measures were based on validated functional categories
from the Vignos Lower Extremity Scale,44 which aligns with the National Heart Blood Lung
Institute’s (NHBLI) recommendations on estimating MCID values for diseases that have a wide
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heterogeneity and also shown to be better applicability in clinical interpretation and efficacy
trials.45-47
RESEARCH QUESTIONS:
As boys with DMD get older and weaker, contractures, strength, and function are
expected decline. However, differences in rates of decline based on functional groups is not
known. Due to the variability in rates of functional decline in boys with DMD, there are expected
differences in these 5 functional groups. With the different musculoskeletal, respiratory and
equipment needs for boys in these 5 groups, this information will be helpful in anticipatory
planning for clinical decision making. Additionally, understanding these changes based on age
and function will help clinical trials group boys with DMD into more homogenous groups to
decrease phenotypical variability thus requiring smaller sample sizes. This study aimed to
characterize the relationship of contracture, strength, and timed function tests based on the 5
functional stages (Diagnosis; Early, Middle, Late Ambulatory; Early, Late Non-Ambulatory) and
estimate MCID in boys with DMD in the corticosteroid era. The research questions that were
addressed in this study:
1. How does ankle ROM, knee strength, age and GC use affect loss of functional abilities
such as ability to walk, get off the floor and climb stairs for boys with DMD.
2. What is the MDC and MCID values for 3 validated and commonly used timed function
tests (10MWT, Supine to Stand, and 4 Stair Climb) to assess disease progression for
individuals with DMD.

10

Rationale
Since the 3 timed test velocity scores have been determined as a good clinical predictor
of loss of ambulation in individuals with DMD,5, 10 the researcher determined the degree that
knee strength and ankle range of motion impact changes in timed function velocities. Previously
published research regarding contractures and function in DMD have analyzed the entire
population of boys with DMD. This analysis focused on the 5 functional groups to better
characterize strength, function and contracture declines in a more homogenous fashion. With the
appropriate stratification of disease stages in DMD, the results of the research study explored the
impact of strength and ROM on function for individuals with DMD, in order to improve
anticipatory care management.
Since there is no consensus in the literature on determining responsiveness of these clinical
measures, an anchor based approach was used.45 Most published studies in DMD which have
looked at determining clinical differences have used both MCID and MDC. There are advantages
to each of these techniques, but based on review of literature in other progressive disease
groups,45, 48, 49 a longitudinal anchor-based approach was sued as it is most relevant to the
progressive nature and variability of DMD.49 Estimates of MCID for functional velocity
measures (10mwt, supine to stand, 4 Stair climb) were anchored to the Vignos Lower Extremity
Scale, a validated 8-point ordinal scale in DMD categorizing lower extremity function.44 This
approach aligns with the National Heart Blood Lung Institute’s (NHBLI) recommendations on
estimating MCID values for diseases with a wide heterogeneity and also shown to be better
applicability in clinical interpretation and efficacy trials.45-47
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To understand the impact of changes in function, MCID in timed velocity scores were
anchored the Vignos Scale. Most studies using MCID scores focus on determining the MCID
required to detect changes in treatment.50, 51 Despite the paucity of research45, 52 using natural
history studies to determine MCID scores, this work used DMD natural history to determine
MCID scores associated with prediction of loss of function, instead of treatment effectiveness.
This is a logical choice given the progressive nature of DMD. In a study of Chronic Obstructive
Pulmonary Disease, a retrospective study assessed MCID values to determine 6MWT MCID
values that may be good predictors of mortality or hospitalization, and found that observational
studies were more robust to answer these questions because of the lack of confounding treatment
interventions.45 In this study, the researcher examined MCID scores as possible predictors of loss
of ambulation.
OBJECTIVES
A. Determine the relationship between knee extensor muscle strength (measured by
Quantitative Muscle Testing (QMT)) and 3 functional timed tests: 10-meter walk test, 4
stair climb and supine to stand in boys with DMD.
B. Determine the relationship between ankle dorsiflexion joint range of motion (measured
by goniometry) and 3 functional timed tests: 10-meter walk test, 4 stair climb and supine
to stand in boys with DMD.
C. Determine if strength and ROM are significant predictors of 3 timed function tests
(10MWT, Stairs, Supine to Stand)
D. Estimate MCID and MDC values of 3 timed functional assessments for individuals with
DMD
12

a. for 10-meter walk/run (10MWT)
b. 4 stair climb (4SC)
c. supine to stand (STS)
IMPACT
With the alteration in the disease course due to standard use of corticosteroids for disease
management and the recent developments in drug therapies, there has been great interest in
understanding the downstream effects of contractures on strength and function across the
spectrum of disease progression. Improvements in standards of care including management of
primary and secondary effects of DMD with GC use, respiratory care, coronary care, and
contracture management have been linked to longer lifespans.53 The economic impact of longer
survival is associated with much higher medical costs, especially in the later stages of the
disease. Medical costs are nearly six times higher for those who are non-ambulatory compared
to those who are ambulatory.54 Thus, making it more important to better understand the reasons
that contribute to loss of ambulation. When it comes to direct medical costs compared to indirect
costs linked to loss of work time or copays, Ryder et al53 found that for those who are nonambulatory, the indirect costs are more than 2.5 times the amount of direct medical costs,
resulting in increased time and financial burden on the family.
Understanding the impairment-based changes that affect the biomechanics of gait and related
loss of functional activities will influence proactive physical therapy clinical decision-making
through prophylactic range of motion management through stretching, bracing, assisted active
range of motion and exercise.4 Boys with DMD have increased bone fragility and fractures due
13

to prolong use of GC, progressive muscle weakness on bone health.55 Management of
contractures may allow longer time standing and walking thus reducing osteoporosis risk and
medical costs associated with being non-ambulatory. By understanding these changes, clinicians
may also anticipate loss of ambulation and risk of falls due to weakness and lack of ROM as
these boys are also at a higher risk of fat embolisms long bone fractures thus adding to medical
costs.56
Due to the multi-organ effects of DMD and multitude of needs that go alongside changes in
the 5 major stages of DMD progression (Figure 1),42 understanding and determining MCID
values in DMD may greatly impact the interpretation of functional changes commonly used in
the clinic, such as the 10MWT , supine to stand, and stair climb. Better understanding of the
prediction of loss of function will contribute to anticipatory care planning for physical therapy in
contracture management and improve planning to obtain appropriate assistive devices that
promote independence and decrease caregiver burden. Additionally, MCID values will help in
designing clinical trials that use study endpoints that show clinical relevance.48
MCID values have typically been reported in intervention-based clinical trials, however, a
few studies have looked at the MCID values on progressive diseases such as COPD,
Huntington’s, cancer, disease, cancer, multiple sclerosis, and Pompe disease.45, 48, 49, 57-59
Determining MCID values in the context of disease deterioration is important to understand the
true impact of future therapeutic interventions. Applying MCID values to commonly used
clinical assessments helps appropriately power clinical trials. MCID is assessed based on rate of
disease progression on an untreated population. Understanding the etiology, symptomology, and
14

natural history of degenerative diseases is essential in determining MCID values that are relevant
to the prediction of loss of functional milestones and its impact on the health-related quality of
life measures.45
Results from this study may greatly impact clinical decisions, outcomes, insurance
reimbursements, and design of clinical trials in DMD. They will also aid in better understanding
of ankle contracture development and conservative approaches to management of these
contractures, which will ultimately contribute to improved standardization of physical therapy
care in DMD. There are currently no studies that assess the frequency of use of braces and
stretching on contracture development, and its associated impact on gait velocity and timed tests.
Since gait velocity has been shown to be a good predictor of loss of ambulation,35 it is important
to understand the impact of contractures on gait velocity, given that contracture management and
corticosteroid use are the few published interventions that have changed the natural history of the
disease.3, 5, 6, 8, 13, 14, 32, 34-36, 60-62
Additionally, the determination of MCID values functional timed tests will aid in clinical
research design by establishing clinically relevant endpoints that are associated with meaningful
change for individuals with DMD. Koynova et al63 performed a literature review of MCID
measures used in clinic research and found that MCID measures must be based on reliable
outcome measures and based on a specific disease group and functional level. Values determined
in this manner may show better responsiveness to changes in disease progression compared to a
more heterogeneous group that encompasses both the ambulatory and non-ambulatory
populations.49 The NIH Heart, Lung and Blood Institute (NHLBI) supports the stratification of
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progressive clinically heterogeneous diseases by taking into account genotype, phenotype,
symptoms, and functional measures to ensure better applicability of MCID values and
validation.45
This study determined MCID values for rate of decline in timed tests over a 12 month period
based on the natural history of the disease. This will impact power analyses used in large multicenter clinical trials to determine sample size and contribute to better validation of the
appropriate measures used for ambulatory boys with DMD to reduce the amount of assessments
required in clinical trials. Not only is DMD a rare disease, but recent DMD therapeutic
discoveries 64, 65 have been based on specific genetic mutations, making clinical trials recruitment
even more difficult. Therefore, having accurate MCID values that reflect rate of decline that is
associated with loss of clinical milestones is important to understand possible impact of new
treatments on the disease progression. Additionally, it may help reduce patient burden by
reducing the number of outcomes required in clinical trials, decrease costliness of large clinical
trials with more accuracy in calculating sample size, and contribute to better clinical
interpretation and standardization of clinical care in DMD.
ABBREVIATIONS:
10MWT

10-meter walk/run test

6MWT

6-minute walk test

CDC

Centers for Disease Control

CE

Clinical Evaluator

CINRG

Clinical International Neuromuscular Research Group

ClinRo

Clinician-Reported Outcome Measure
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COA

Clinical Outcome Assessment

DMD

Duchenne Muscular Dystrophy

FDA

Food and Drug Administration

EMA

European Medicines Agency

GCP

Good Clinical Practice

HHM

Hand Held Myometry

ICF

International Classification of Function and Disability

IM

Investigators Meeting

LOA

Loss of Ambulation

MCID

Minimal Clinically Important Difference

MDC

Minimal Detectable Change

MMT

Manual Muscle Testing

MRC

Medical Research Council

MVICT

Maximal Voluntary Isometric Contraction Testing

NIDRR

National Institute on Disability and Rehabilitation Research

NIH

National Institutes of Health

NMD

Neuromuscular Disorder

NSAA

North Star Ambulatory Assessment

PODCI

Pediatric Outcomes Data Collection Instrument

PRO

Patient Reported Outcome Measure

QC

Quality Control

QMT

Quantitative Muscle Testing

ROM

Range of Motion
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SOC

Standards of Care

SOP

Standard Operating Procedure

TFT

Timed function tests

WHO

World Health Organization

DEFINITIONS:
Clinical Evaluator (CE): Individual, often a physical therapist, who will perform clinical
research assessment of outcomes that will be implemented in clinical trials or in the clinic.
This individual will have training in implementation of clinical research assessment of
outcomes in a standardized manner following good clinical practice66, 67.
Neuromuscular Disorders (NMD): Disorders that impair functioning of muscle (directly or
indirectly) and originate from: anterior horn cells, nerves, neuromuscular junction, muscle
and peripheral nervous system pathology5, 8, 67-70.
Cooperative International Neuromuscular Research Group (CINRG): Consortium of 26
national and international sites who participated in the Duchenne Muscular Dystrophy
Natural History Study29, 30
Contracture: Shortening or hardening of muscles, tendons, or ligaments that may lead to
loss of range of motion at joints7, 11, 38
Duchenne Muscular Dystrophy: A genetic disorder characterized by progressive muscle
degeneration and weakness due to lack of dystrophin4.
Gower’s Maneuver: A maneuver that describes how a patient must use their hands to
“walk” up their body to get up from the ground due to proximal weakness6.
Minimal Clinically Important Difference (MCID)/ Minimal Important Difference
(MID): the smallest difference in a clinical outcome that a patient would identify as
important46
Minimal Detectable Change: Statistical estimate of smallest amount of change that may be
detected by a clinical outcome 71
Dystrophin-Associated Protein Complex: Structural protein that links the actin
cytoskeleton to the extracellular matrix acting to stabilize the sarcolemma.
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MDX Mouse: Mouse model with a point mutation in the dystrophin gene, typically used for
early animal research.
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CHAPTER 2
INTRODUCTION
Duchenne Muscular Dystrophy (DMD) was first described in the medical literature in
the 1850s, yet the molecular basis for the disease was not identified until the 1980s.4 The gene
responsible for DMD, dystrophin, is one of the largest in the body with 79 exons.4 Since this
discovery, scientists have been trying to understand the pathophysiology of the disease by
studying the MDX dystrophin-deficient mouse model. The MDX mouse has provided the
scientific community with a better understanding of dystrophin’s function in skeletal, smooth
and cardiac muscles.72
As basic scientists worked to understand the pathophysiology of DMD, clinicians were
also working on better characterizing the clinical features of this x-linked disorder. Individuals
were first diagnosed due to motor delays, elevated creatinine kinase levels, a positive Gower’s
sign, and pseudo hypertrophic calf muscles.73, 74 Currently, molecular advances have led to
improved diagnostic abilities, where individuals who show the clinical signs of DMD may be
confirmed to have DMD through genetic testing instead of the previously used method of
confirmation by muscle biopsy. Clinical care has focused on managing the symptoms of the
disease in absence of a cure. Pharmacologic treatment with the corticosteroid prednisone has
changed the natural progression of DMD by alleviating the severity of muscle decline and
prolonging ambulation by as much as 2 years.61 Because of the progressive nature of this disease,
rehabilitation to return to a previous functional level is not a realistic goal for individuals with
DMD. Therefore, physical therapy interventions aim to address the chronic progressive nature of
symptoms of DMD such as decreased activity from progressive strength loss, contractures, and
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pain. Management includes adaptive exercise, stretching, bracing, and positioning to improve
quality of life for individuals with DMD.7, 14, 75-77
The DMD community has worked diligently towards a cure for this disease by learning
and better understanding 1) the pathophysiology behind dystrophin deficiency; 2) clinical
features and progression rates in boys with DMD; and 3) development and use of clinical
outcomes to better understand and predict the variability of DMD for improved care
management and clinical trial design. The clinical endpoints (10MWT, supine to stand, 4-stair
climb) described in this research project are used in the clinical setting but were developed in
natural history studies to better understand the variations seen in the phenotypical presentation of
DMD. With better understanding of the impact of these clinical endpoints on disease
progression, clinicians started to use these as assessment tools to manage patient care. This
represents a great example of translational science where academically developed tools are used
to affect clinical care. However, these tools need further development to understand variables
that affect change in functional status as well as contribute to clinical trials design.
DMD PATHOPHYSIOLOGY
Dystrophin is the gene associated with DMD. It was fully cloned and sequenced in 1988
and led to the identification of large complex proteins that play an important role in muscle
physiology.4, 78, 79 At a cellular level, the lack of the structural protein dystrophin leads to
progressive muscle weakness associated with disruption in the degeneration and regeneration
cycle of repair, in which the muscle fibers undergo irreversible degradation with resultant muscle
fibers being replaced by adipose and connective tissue.
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In skeletal muscle, dystrophin is found on the plasma membrane as a part of the
cytoskeleton that may play a role in protecting the sarcolemma from mechanical stress from
stretch-induced contractions.80 It helps link the cytoskeleton and the extracellular matrix as part
of the Dystrophin-Glycoprotein Complex (DGC).72 The DGC is a “shock absorber” that
maintains sarcolemma integrity during muscle contractions.81 Disruption of the DGC pathway
leads to destabilization of the sarcolemma, disturbed cellular defense mechanisms, and impaired
calcium homeostasis resulting in mechanical damage to muscle fibers, loss of cell integrity, and
necrosis.82 Costameres and other proteins form a lattice that anchors to the sarcolemma and acts
as a mechanical coupler to distribute contractile forces along the length of the muscle fiber leads
by maintaining uniform sarcolemma length. The absence of dystrophin contributes to muscle
membrane fragility, so its dysfunction also causes increased membrane permeability and
accumulation of excessive proteins not normally present in muscle membranes. Calcium
homeostasis is essential to muscle function, and increased accumulation of calcium leads to
gradual reduced regenerative capacities and increased necrosis. Ultimately this results in fatty
tissue infiltration with subsequent muscle weakness and decreased functional contractile
myofibers.72, 83
Since dystrophin provides mechanical stability to the sarcolemma, force transmission
may be impaired between the intracellular and extracellular matrix that is enveloped by the
muscle fiber and connected to the muscle tendon.84 Therefore, the combination of compositional
changes and structural instability leads to muscle weakness, starting proximally with larger
muscle groups and followed by distal weakness. In addition to the fatty infiltration and
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connective tissue found between muscle fibers in DMD, muscle biopsies showed progressive
degeneration/necrotic muscle fibers that are generally surrounded by lymphocytes and
macrophages with variations in muscle fiber size and centralized nuclei. The immature central
nuclei represent regeneration of myoblasts. This results in an imbalance between degenerating
and regenerating fibers.73, 85 As the disease progresses, the capacity for muscle fibers to
regenerate diminishes resulting in replacement of the muscle tissues with connective or adipose
tissue. This pathophysiological imbalance between myoblast regeneration and muscle fiber
necrosis leads to progressive muscle weakness in DMD.82
Animal models have typically been used to understand the pathogenic mechanisms
behind DMD and therapeutic targets. The best way to fully understand the complexities of DMD
would ideally be to perform serial muscle biopsies, but due to the ethical implications and
invasiveness of these procedures, dystrophin-deficient animal models are used to better
understand the mechanism of disease. The MDX mouse has been used for over 30 years and is
the most studied of all the animal models. The MDX is genotypically identical to DMD, but
phenotypically less severe. Another model, such as the golden retriever muscular dystrophy dog
(GRMD), has also been used in preclinical trials as it is phenotypically much more similar to
DMD than the MDX mouse. However, ethical and financial issues resulted in the GRMD models
being primarily used for promising therapeutic agents, whereas the MDX mouse model has
remained the primary preclinical model for studying DMD. An exercise regimen implemented in
MDX mice has been shown to exacerbate the imbalance between muscle degeneration and
regeneration seen in DMD, therefore this model has been suggested to this regiment better
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represent the DMD clinical presentation.86 Similar to DMD clinical trials, preclinical outcomes
have established standardized techniques to ensure consistency across MDX trials.87
Additionally, reliability and sensitivity of measures were established to determine best
preclinical outcomes to assess change in disease progression.88 Despite the challenges and
differences seen in the MDX mouse, it is still the most utilized preclinical model to study disease.
However, researchers must understand the limitations and interpretation of data that come from
preclinical MDX trials due to the phenotypical differences. That being said, without this model,
the DMD community would not have the pathophysiological understanding of the disease and
there would be fewer therapeutic treatment options for clinical trials.
Since the discovery of the dystrophin gene, the DMD diagnostic process has greatly
improved. Diagnosis was originally obtained through a muscle biopsy where a southern blot
analysis was performed to identify large deletions. The problem with this method is that only
65% of DMD are due to deletions detectable though southern blot analysis; the other 30% have
point mutations or small deletions, while 5% have duplications.
The lack of dystrophin production due to a truncated or deleted dystrophin gene is the
reason for variations in phenotypic manifestations of the disease. The differences in clinical and
biochemical presentation depend on the mutation. Dystrophin that is expressed in an open
reading frame results in a milder form of DMD called Becker muscular dystrophy (BMD), in
which dystrophin is partially present. Patients diagnosed with DMD have an in-frame deletion
resulting in complete loss of dystrophin.89 Dystrophin has many functions in both the cardiac,
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skeletal and smooth muscles of the body. In this research study, we will focus on the mechanical
effect of lack of dystrophin in skeletal muscle resulting in skeletal muscle weakness.
In DMD, some of the primary consequence of dystrophin deficiency relate to sarcolemma
instability, impaired calcium homeostasis and glycosylation between the Dystrophin-Associated
Protein Complex (DAPC) and the extracellular matrix.90, 91 The DAPC is made up of 3
subgroups with a focus in dystroglycans of which dystrophin is the most relevant to DMD. Some
theories on secondary effects associated with disease severity are related to tissue remodeling
and chronic inflammatory changes.
Some of the physiologically based theories on the variability in disease progression are
related to the effects of tissue remodeling and inflammation. In vivo studies of macrophages
show that reduced levels of CD4+, CD8+ or macrophages significantly reduce the pathology in
MDX mouse models.82 Activation of inflammatory pathways occurs as early as 8-10 months, but
then remains relatively stable throughout the disease course despite the muscle degeneration that
occurs later in the disease progression. Damaged or stressed cells trigger an immune-response
leading to overactivation of the TGFB2 pathway resulting in chronic inflammation.92
The lack of dystrophin leads to a cascade of pathophysiological decline resulting in
muscle fiber degeneration. The degenerative process incapacitates the muscle’s regenerative
capabilities, resulting and in muscle fibers being replaced with fat, connective tissue and
fibroblasts decreasing with a decrease in muscle contractility and ultimately strength. Alongside
is this loss of muscle strength there is a process of chronic inflammation that further triggers
muscle degeneration and contributes to strength declines.
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DMD CLINICAL PRESENTATION
DMD is the most prevalent of childhood neuromuscular diseases with an occurrence of 1
in every 7250 males.2, 3 DMD is an x-linked inherited degenerative disorder, however,
approximately 30% of cases arise from spontaneous mutations.93-95 Duchenne was initially
described as a severe muscle wasting disease with muscle weakness and pseudohypertrophy.96
DMD primarily affects skeletal and heart muscle with premature death from cardiorespiratory complications.40, 97 The onset of weakness occurs between 3 to 5 years of age and is
characterized by motor delays, increased falling, inability to run or climb stairs, muscle cramping
and fatigue. Complications include a combination of impairment-based weakness and a
decreased range of motion with impact on functional mobility.
Throughout development, muscle imbalances lead to the development of contractures,
scoliosis, and progressive impairments of respiratory and cardiac capacity.5, 8 Many children who
are diagnosed with DMD show early signs of functional motor delay. Proximal weakness and
contracture development lead to progressive difficulty performing functional activities.
Difficulty rising from the floor and running, along with and frequent falling are usually the first
signs that lead to the initial investigation of the possible causes for these motor deficits. Boys
with DMD are generally diagnosed around 5 years of age, when teachers and family observe
their inability to keep up with their peers, difficulty getting up from the floor, or a waddling gait
pattern. The progressive decline in strength results in sequential loss of functional mobility from
the inability to stand up from the floor, to later inability to stand up from a chair and eventual
loss of independent ambulation.
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Confirmation of diagnosis is usually made from a combination of clinical observations and
genetic testing. Clinical assessments include observations of pseudohypertrophy of the calves, a
positive Gower’s maneuver, and proximal muscle weakness. Laboratory; tests may confirm
extremely high creatine kinase values, as well as elevated transaminases (aspartate
aminotransferase and alanine aminotransferase produced by muscle and liver cells).21
Along with an adaptive Gower’s sign, children with DMD have difficulty obtaining some
gross motor milestones such as jumping, hopping, reciprocal stair climbing, and experience
frequent falls. 9 Clinical progression rates are variable, but occurs in a predictable, sequential
manner20 starting with loss of the ability to get up from the floor, climb stairs, walk, feed oneself,
and early mortality from cardiac and respiratory complications.5, 6, 8, 13, 14, 21, 22 Birnkrant42 et al
Care Considerations defined stages of DMD based on the functional loss of ambulation as
(Figure 1) Pre-symptomatic; 2) Early Ambulatory; 3) Late Ambulatory; 4) Early NonAmbulatory; and 5) Late non-ambulatory. In the pre-symptomatic stage of the disease, boys may
gain motor skills up to 7 years of age, but continue to fall behind their peers.98 After 7 years,
there continues to be a progressive decline in muscle strength and function throughout the
disease course. Significant clinical milestones are lost in a sequential manner throughout the
ambulatory and non-ambulatory stages of the disease. Individuals who are still ambulatory first
show a Gower’s sign, then progressively lose the ability to get up from the floor, to climb stairs,
and to walk. After loss of ambulation, individuals lose the ability to get hands to the head for
grooming, bed mobility, hands to mouth for eating, coughing, ability to get hands on the table,
ability to use the computer/phone, and the ability to drive a wheelchair even with adapted micro
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joysticks.5, 6, 8, 13, 14, 21, 22 DMD is technically a muscle disease, but it affects multiple organs,
therefore disease management is based on a multi-disciplinary approach (Figure 1). For the
purposes of this project, the focus will be on the progression of contractures and strength
declines in boys with DMD.
FIGURE 1 CARE CONSIDERATIONS FOR DMD
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MUSCLE WEAKNESS
Pathophysiological muscle changes typically occur first in proximal large muscles such as
pelvic and shoulder girdle muscle, and progress to distal muscles.99-103 Lower extremity muscles
that are affected first include the gluteus maximus, adductor magnus, then quadriceps and bicep
femoris. 102-107. Strength has been assessed in DMD by manual muscle testing using the Medical
Research Council (MRC) ordinal grades, quantitative muscle testing, and more recently
magnetic resonance imaging (MRI). Manual muscle testing data has shown that strength loss is
linear starting at 6 years of age.5, 108 Young boys between ages 4-6 years with a manual muscle
test (MMT) grade of 4 (moderate resistance against gravity) showed a 40-60% difference in
isometric strength compared to age-matched healthy controls.5 Decreased isometric quantitative
muscle strength of nearly 50% was seen in knee and elbow extensors by the age of 6 years
compared to children without DMD.5 Loss in function for both upper and lower extremities
correlated with the ability to contract muscles against gravity (MRC grade 3).5 Similar to many
neuromuscular diseases, the rate of change during the teenage years is greater and appears to
coincide with the loss of ambulation. 5
Magnetic Resonance Imaging and spectroscopy (MRI/MRS) testing has provided further
understanding of muscle degradation in DMD. MRI studies have shown that during the
transitional ambulatory stage of DMD (9-13 years) there was a faster rate of fatty infiltration of
the muscle.109 Distal lower limbs show significant fatty infiltration in the soleus and tibialis
anterior, with the peroneus muscle having the most lipid infiltration.101, 106, 110 Muscles that
appear to show sparing are the hamstrings and adductor muscles.106, 111 These publications
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appear to explain some of the possible contracture development and gait abnormalities seen in
individuals with DMD.
CONTRACTURES
Contracture is a term used to describe the abnormal shortening of muscles, skin or
connective tissue causing restrictions in active and passive ROM.8, 112 Contractures are prevalent
and inevitably develop in many pediatric neuromuscular disorders.113 Joint contractures can
result in a number of disabling complications such as orthopedic deformity, pain, and decreased
function and mobility. These complications have direct impacts on activities of daily living
(ADL) and quality of life. The underlying pathology of dystrophic muscles contributes to the
nature of muscle weakness, contracture development, and progression.
Contractures are typically categorized into 2 primary groups (physiological or myostatic)
based on the etiology of their development. Most physiologically based contractures result from
upper motor neuron defects, physiological processes, or electrolyte imbalances. Myostatic
contractures, which are most common in NMD, result from immobilization or muscle
weakness/imbalances.
Contractures in DMD are myopathic in origin. Contractures are more prevalent in
myopathic disease as patients typically have proximal weakness, compared with neuropathic
diseases which have more distal weakness.113 Loss of joint ROM typically occurs due to fibrosis
and fatty tissue infiltration of the muscle, and develops alongside progressive muscle weakness
and imbalance. This causes increased passive resistance and non-contractility in the
endomysium, perimysium and epimysium, contributing to shortened muscle fibers.114 A study of
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dystrophic muscle found that the non-contractile component highly correlated with muscle
strength and function.115 Increased stiffness within the muscle fibers reduced contractile force,
whereas stiffness in passive structures such as tendons and connective tissues was associated
with severity of contracture.114, 116, 117 The reduction in sarcomeres as a result of the pathological
process changes the force tension curve, causing shortened muscles and contracture formation.
Contractures can be a critical clinical marker for DMD, with significant value in
diagnosing and tracking progression. With DMD, contractures appear to develop alongside
weakness patterns. Contractures in weight-bearing joints such as knees and ankles appear to be
most debilitating as they affect walking. The inability to actively move a joint through full
available ROM is one of the leading causes for fixed contractures because it results in static
positioning of limbs, shortening of muscle fibers, and decreased sarcomeres.
Muscles that cross multiple joints are at higher risk of contractures compared to those that
only cross one joint, since multiple-joint muscles must have sufficient flexibility to allow both
joints to move through full range. Bi-articular muscles have origins and insertions crossing two
different joints and have greater risk of change within the length-tension curve for muscle force
production when they develop contractures. Biarticular muscles serve multiple roles in
movement, especially in closed-chain activities which constitute most functional mobility tasks.
With isometric contractions, bi-articular muscles assist in controlling movement through the
range. Examples of muscles that fall into this category are pectoralis major, biceps brachii,
pronator teres, rectus femoris, tensor fascia latae (IT band), and gastrocnemius. As a result of
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muscle weakness in DMD, these muscles are not stretched to their full functional range across
both joints, inhibiting appropriate biomechanics for movement and tissue shortening.
To better understand contracture development in boys with DMD, it is important to
understand the patterns of weakness and imbalance unique to the disease. Muscle weakness is
initially seen in proximal muscles including the hip flexors/extensors and knee extensor
muscles.8 However, contractures typically develop first in ankle plantarflexors, followed by hip
flexors, hip abductors and knee flexors.8 This is largely caused by the number of biomechanical
adaptations made by patients to maintain standing and ambulation. When looking at torque
production and association with contractile versus non-contractile tissue, a study by Akima et
al115 noted that there was not an age-related decrease in specific force production compared to
controls. In boys with DMD, torque was more closely related to functional assessments such as
supine to stand, timed up and go and walk/run assessments.115 Recently, studies on crosssectional area and torque production in boys with DMD validated this observation, showing a
decline in specific torque compared to controls, specifically in the gastroc-soleus complex and
tibialis anterior groups.118 Armand et al119 found that plantarflexion strength is the greatest
predictor for loss of ambulation. Quadriceps and plantarflexor strength? showed the highest
correlation with functional activities such as getting out of a chair and walking (Figure 2).118
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FIGURE 2 DISEASE PROGRESSION AND ASSOCIATED TIGHTNESS

The unique combination of contracture development and weakness leads to a standing
posture of increased plantarflexion, hyper-lordosis, and an anterior pelvic tilt. This alignment
creates a biomechanical advantage that causes an extensor moment arm that allows for
maintenance of upright standing, despite dorsiflexion range deficits and quadriceps weakness.
With progressive plantarflexion contractures, this moment arm becomes smaller, producing less
of an extensor moment at the knee to maintain upright posture. Additionally, as the hip extensors
become weaker, a larger compensation becomes necessary in order to support the overall
extensor moment needed to stand upright. The muscle imbalance between hip extensor weakness
and hip flexor tightness causes a pelvic anterior tilt and contracture of the hip flexors resulting in
a compensatory lumbar hyperlordosis resulting in a shift of the line of gravity posteriorly to
produce an extensor moment.15 Additionally, the line of gravity then falls anterior to the knee
causing an extensor moment to remain upright.
While individuals are still ambulatory, lower extremity contractures are less prevalent and
severe. Biomechanical changes allows boys with DMD to maintain the ability to walk for a
longer period of time despite the lack in muscle strength, but result in a less efficient gait pattern
with increased energy demands.120 Progression of gait compensations follow the course of
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muscle weakness and contracture development with a sequential pattern of toe walking,
increased base of support, lumbar hyperlordosis, circumduction of the lower extremities with no
midrange knee flexion, no push off through swing phase, and increased use of upper arms and
trunk to provide forward propulsion momentum.15, 121-125 Boys with DMD develop plantarflexion
contractures, which along with an increased lumbar lordosis help shift their line of gravity
posteriorly at the hip and anteriorly at the knee. This leads to the adoption of compensatory
strategies with a more inefficient but stable gait pattern, equinus posture and excessive lumbar
lordosis. Postural compensations allow boys with DMD to stay upright, but result in decreased
gait velocity and contribute to eventual loss of ambulation.15-18 Electromyographic (EMG)
studies have found increased coactivation of rectus femoris and hamstrings as well as tibialis
anterior and gastroc-soleus complex in DMD to maintain gait stability.120 During stance phase,
due to hip and knee extensor weakness, there is a shift in the loading response and decreased
vertical ground reaction force which displaces the body anterior to the center of gravity (COG)
resulting in abnormal knee flexion contributions to lower limb stability.18, 123, 126-128 During
swing phase, boys with DMD tend to hike their hips with a lateral trunk lean due to weakness of
the hip flexors, specifically iliopsoas, and abductor muscles.16, 128
Declines in muscle strength along with the development of contractures lead to adopted
compensatory postures to preserve function such as Trendelenburg gait and excessive
plantarflexion throughout the gait cycle. Although initially a functional adaptation, with time
muscle weakness and contractures become so severe that patients with DMD are unable to rely
on these compensations to maintain upright standing. Ankle/foot contractures progress from loss
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of dorsiflexion range to loss of mid to forefoot range into eversion, due to a combination of
weakness and positioning of the feet while sitting in a wheelchair (Table 1). In the later stages,
the IT bands become tighter, pulling the hips into external rotation and leading to primary
weight-bearing on the lateral border of the foot. This pattern contributes to positional shortening
of the inversion muscles of the foot, leading to more severe equino-varus with pain and difficulty
wearing shoes/socks.
TABLE 1: ANKLE CONTRACTURE PROGRESSION
Ankle Contracture Progression
Contracture
Description

Loss of range in dorsiflexion

Loss of range in eversion

Loss of range in midfoot
rotation & eversion

Loss of ambulation

Loss of weight-bearing in
transfer

Increased pain and difficulty in
positioning

Example
Image

Functional
Loss
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Stretch
Direction

•

Dorsiflexion

+ Dorsiflexion and Eversion
Images by Kate Witherspoon

Time required to complete a task has been used to predict functional milestone loss in DMD,
such as loss of ambulation. Because the loss of clinical milestones occurs in a variable yet
sequential manner, the time it takes to complete functional tasks (supine to stand, climb 4 stairs
and walk/run 10 meters) has been used to predict loss of function. These predictive values are
important in clinical trials as well as care management. For example, individuals who take > 12
seconds to ambulate 10 meters will likely require a wheelchair for mobility within a year.5 This
allows clinicians to speak to the family about ordering a wheelchair, home modifications,
planning for school with modifications in the Individual Education Plan (IEP), and numerous
other life changes that come along with losing ambulation. In clinical trials, it is important for
trials to be able to predict loss of ambulation so that they define the study inclusion criteria to
mitigate the risk of individuals losing the ambulation during a clinical trial. Even though work
has been done on the prediction of these losses, minimal work has been done on understanding
the impairments leading to decreased walking velocity, which is an observable variable
precluding the ultimate loss of ambulation. Recently, a study by Ropars, et. al.129 examined
muscle activation using EMG during gait among boys with DMD, and found that there is
36

increased co-activation at the knees and ankles to maintain stability during gait. Due to the
profound proximal weakness at the hips, individuals with DMD used agonist/antagonist
coactivation of the rectus femoris and hamstrings, and tibialis anterior and gastric-soleus
complex, to provide stability during gait. Additionally, the authors found a positive relationship
between gait velocity, Vignos score, and co-activation of these muscle groups.129 Due to the
progressive nature of DMD, approaches to physical therapy are to provide adaptations to
preserve function instead of normalizing movement patterns. Findings from the Ropars120 study
have a clinical impact on physical therapy interventions which indicate that increasing coactivation exercises and possibly providing better ankle support by using orthotics for individuals
with fixed ankle contractures may be beneficial to support a stable, energy efficient gait for
individuals with DMD.
CURRENT THERAPIES
Therapies in DMD have evolved since the discovery of the dystrophin gene along with an
improved understanding of the physiological roles of dystrophin in muscle and other organs,
however, there are still limited treatments that delay the progression of the disease. Treatments
that have changed the landscape of DMD include corticosteroid medications (GC), improved
respiratory management with non-invasive ventilation, and physical therapy interventions for
management of contractures to promote functional mobility throughout the lifespan. These
therapies have impacted disease progression, however, boys with DMD continue to lose function
throughout the lifespan with early mortality. Academicians and pharmaceutical companies have
focused on DMD-specific drug development including antisense oligonucleotide therapy (AON)
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mediated exon skipping, small molecule compounds, stem cell therapy, gene transfer, and
muscle growth promotion (utrophin, myostatin inhibitors, GC equivalents).
CORTICOSTEROID TREATMENT (GC)
Multiple preclinical and clinical studies have shown that GC treatment decreases the
progression of DMD.6, 26, 28, 36, 130-136. GC treatments include the use of prednisone, prednisolone
and deflazacort. These may be described as “corticosteroids” or “steroids.” Dosages for GC
therapy range from 0.3mg/kg/day to 1.5 mg/kg/day with a variety of regimens from daily or
alternate days to higher weekend only doses.32, 35, 61, 137, 138 The most commonly recommended
dose of GC is 75 mg/kg/day however these other regimens have been studied to try to mediate
some of the side effects associated with GC use. Until the first approval of an anti-inflammatory
drug deflazacort, Emflaza, in February of 2017, prednisone or prednisolone were has been
recommended and prescribed but never an official FDA approved treatment for boys with
DMD.139 Despite all of the studies indicating the efficacy of GC for individuals with DMD, the
mechanism of action is still unknown. Multiple studies have hypothesized possible benefits
ranging from myoblast proliferation, stabilization of the muscle membrane, anti-inflammatory
effects, decreased cytosolic calcium, upregulation of utrophin, or improved regulation of muscle
fiber genes to an increase myogenic repair.33, 34, 140-143 The reported short-term benefits of GC
come with undesirable long-term consequences, although studies have not researched GC
treatment for more than 2 years to adequately report on the effects of long-term use.130 Reported
side effects vary but include behavioral changes and irritability, hyperactivity, Cushingoid
features, osteoporosis, weight gain, short stature, cataracts, hypertension, hyperglycemia, and
delayed puberty.30, 36, 40, 54, 61, 62, 135, 144-146
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Based on the 2018 SOC21, 42, 43 boys with DMD should be treated with GC. At around the
time of the initial SOC recommendations in 2010, a population-based study found that >50% of
boys diagnosed with DMD are treated with GC.147 A more recent study by the Muscular
Dystrophy Surveillance Tracking and Research Network (MDSTARNET) published in 2015
reported that 54% of individuals with DMD are not treated with GC.148 With the rapidly
growing clinical trials for DMD in the pipeline where being on a stable dose of GC is a study
inclusion criteria, many more boys with DMD will likely be following this GC recommendation
in the near future. Untreated individuals with DMD typically lose ambulation by the age of 9.710 years, whereas, those treated with GC maintain ambulation to approximately 13.4 years of
age.37, 40
The benefits of GC therapy in DMD were initially reported in the 1970s149 and confirmed by
the Clinical Investigation in Duchenne Dystrophy (CIDD) study group in a randomized control
study (RCT) in the late 1980’s.6, 149 In this placebo-controlled study, they found increases in
manual muscle strength, timed function tests, and respiratory function.6, 32 Recently, a Cochrane
review of 1RCTs in GC therapy found “moderate quality evidence from RCTs indicates that
corticosteroid therapy in DMD improves muscle strength and function in the short term (12
months) and strength up to 2 years”.130 The outcomes used in these studies included time to loss
of ambulation, mean change in muscle score, pulmonary function, walking velocity, supine to
stand, 4-stair climb, Brooke and Vignos scales, as well as composite functional scales such as the
NorthStar Ambulatory Assessment (NSAA).
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When comparing GC treatment versus placebo, most studies, show a significant
improvement with GC therapy, even with varying doses and regimens. Studies comparing
average MRC scores in a 6-month trial showed mean differences in total muscle score between
0.34150 to and 0.45.32 When investigating strength differences between individuals treated with
deflazacort versus prednisone, Griggs et al 151 found that in a 52-week trial there was a 0.38
mean change in average MRC score in the deflazacort treated group compared to a mean change
of 0.23 in the prednisone group.
Most of these studies examined timed function tests as a secondary measure of efficacy. This
includes supine to stand, 10-meter walk test (10MWT), and 4 stair climb. A recent study from
the ACT trial using the 6MWT as the primary efficacy endpoint found a difference in their 48week trial between deflazacort (-39.0 meters) and prednisone (-70.6 meters) treated patients with
DMD. Two studies used the 10-point Vignos Lower Extremity score and found improvements of
a 0.39 point152 and a 0.49 point32 in prednisone treated groups. For timed tests, all studies
found significant differences between the treatment and placebo groups. For the supine to stand
tests, there was an average minimum difference of 2.22 seconds between placebo and GCtreated. 54, 130 For the 4-stair climb test, there was a pooled difference of 3.09 seconds.130 The
10MWT test also showed significant differences which ranged from 1.18 seconds152 to 2.64
seconds.32 These studies show the beneficial impact of GC treatment on strength and function
for up to 12 months in boys with DMD. Currently, only CINRG, has prospectively studied the
long-term effects of GC therapy in boys with DMD. Retrospective studies had already correlated
declines in function to disease progression and found that timed function tests were the best
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predictor of disease progression.5 In a review of data collected in the pre-GC era, McDonald et al
found that boys with DMD who took > 9 seconds to walk 10 meters lost ambulation in 2 years,
while those who took > 12 seconds lost ambulation in one year5, linking walking velocity to
functional decline. The CINRG study published in 2018 found that the time required to
accomplish the 3 timed function tests (supine to stand, 4-stair climb, 10MWT) predicted loss of
function. They found that age of loss of ambulation predicted respiratory progression of a Forced
Vital Capacity(FVC) < 1 liter, which is highly correlated to mortality.40 In DMD, loss of clinical
milestones occurs in a sequential manner first impacting the ability to get up from the ground,
then climbing stairs, and then walking. In a prospective post GC study by CINRG, the
researchers found that loss of the ability to stand resulted in a 70% chance of losing ambulation
within one year, and the inability to climb stairs resulted in a 50% chance of ambulation loss
within the same time frame. This same group used time to event analysis to determine if GC
treatment resulted in faster walking velocity with ultimate delays in loss of ambulation.40 This
data showed that GC treatment indirectly contributed to improved overall survival by affecting
predictive trajectories of the decline of clinically meaningful milestones.
STRETCHING/BRACING/PHYSICAL THERAPY
Stretching interventions refer to techniques or modalities that apply tension to soft
tissues.153 Physical therapists use a number of techniques that elicit short (active and passive
stretches) and long duration (positioning, night splinting, and serial casting) stretches to maintain
or improve joint flexibility.
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Stretching interventions are thought to increase soft tissue extensibility via two different
mechanisms which include initial viscous deformation of the muscle (dynamic phase) and
structural adaptations within the muscle and surrounding soft tissues (static phase).154 Viscous
deformation refers to the initial mechanical response of soft tissue, such as muscle, ligament and
tendon, to sustained stretching that may initiate the “stretch reflex.” The “stretch reflex” is a
transient response that is thought to last as long as the actual stretch time, followed by the static
phase that allows for viscoelastic stress relaxation.155 If a muscle is immobilized in a lengthened
position, longer lasting changes in muscle length occur as a result of structural adaptations taking
place within the muscle.154 Via this mechanism, increases in muscle length occur as sarcomeres
are added in series, and can occur within 48 hours of a muscle being immobilized in a lengthened
position.156-159 This suggests that the duration of the stretch is an important factor in achieving
molecular changes in muscle length. The intensity of the stretch appears to be another important
factor in achieving increases in muscle length. Studies of muscular adaptations following limb
lengthening surgery, in which up to 10 cm in bone length can be gained in a matter of months,
provided evidence that large increases in muscle length are possible with an intense stretch.160
The actual physiology of increased flexibility is unclear, which has led to many different
types of stretch interventions falling under either static (isometric, active and passive) or active;
and more dynamic approaches (proprioceptive neuromuscular (PNF) contract relax, or ballistic
stretching). PNF employs isometric agonist contraction/relaxation techniques based on the
theory of reciprocal inhibition to facilitate a stretch. An individual’s strength will determine
whether they are able to perform some of the active or PNF techniques. Stretching for NMD
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should never include ballistic stretches because the approach uses the body’s momentum to force
a stretch beyond its available range. Many have theorized that a possible mechanism behind
stretching is autogenic inhibition where a muscle relaxes with time, which dampens the stretch
reflexive or other neuro-reflexive mechanism.161, 162 Many people report pain or discomfort
associated with stretching, but many studies have shown that improved stretch tolerance with a
daily stretch routine is the primary factor in improved ROM.117, 153, 163-165 Structures associated
with stretch tolerance are unknown, but it has been hypothesized that tolerance may be related to
nociceptive nerve endings in the muscle. This supports the rationale behind active stretch
techniques, activating an agonist muscle to stretch the antagonist, which appear to have
improved short-term range of motion from enhanced tolerance to stretch rather than muscle
extensibility.117, 153, 165, 166
Management of contractures requires a multifaceted approach with focus on prevention/delay
of contracture development. Due to time constraints, clinicians should prioritize muscle groups
most prone to contractures by first understanding the phenotypical presentation of the
neuromuscular disease. Secondly, a thorough strength exam identifying muscles that lack full
antigravity strength would provide insight on muscles prone to contracture development.
The key to contraction management is prevention with both daily short-duration and
long-duration stretches. Stretch studies in NMD have yielded inconclusive results10 regarding
recommendations for effectiveness of short- or long-duration stretching. A possible explanation
could be the method of measurement of stretch effectiveness. Most studies use ROM as an
indicator for improvement. Multiple studies have shown that ROM is a surrogate marker for
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stretch tolerance, instead of structural or morphological changes or mechanical changes in
viscoelastic properties.117, 161-163 Physiologic factors associated with stretching may compromise
effective stretching in DMD. Changes to molecular and stretch pathways, especially those that
monitor the sensitivity of stretch responses (such as the stretch reflex, Golgi tendon apparatus
and muscle spindle) may hinder normal responses to stretch therapy.
There is a need for standardization of stretching recommendations in DMD. Many
recommendations are from anecdotal reports, rather than randomized controlled trials. These
trials had conflicting results due to lack of standardized interventions and appropriate endpoints
to measure actual tissue extensibility, versus stretch tolerance, which is extrapolated from joint
ROM. Stretch studies address short-duration stretching defined as manual stretches of 15
seconds up to 30 minutes,165 and long-duration stretch managed by bracing or positioning.
Despite the lack of concrete evidence in the types of stretching modalities that should be used for
management, smaller studies and case reports indicate the extreme benefits of daily passive
range on overall muscular and joint health. For individuals who have less active movement, the
significance of stretching becomes greater.
Stretching: Short Duration
Passive stretching involves an external force to passively lengthen muscles, however, activeassisted force by the agonist muscle is required to maintain range of motion. Stretches that are
sustained between 15 sec to 2-minute intervals have been reported165, 167-171 and devices can be
used to assist short-duration stretching. The Kiddy Up Strap KitTM, or similar strap-based
systems, are low in cost and complexity, and can contribute to autonomy in stretching and
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improve the ability to hold a stretch for an increased duration. However, the individual does not
have control over the intensity of the stretch and may require a caregiver to don/doff the device.
Additionally, the device is positioned on the forefoot and lower back, which does not target the
Achilles tendon, thus risks over stretching the plantar fascia in the arch of the foot and adds
stress on the low back.
A study exploring the duration of a static stretch showed that there were no differences
between 30 and 90 second holds in improving stretch tolerance.169 Passive lengthening tended to
activate the stretch reflex, therefore, methods to inhibit the stretch reflex would result in a greater
stretch.172, 173 These methods include activation of the agonist to inhibit the antagonist muscle.
However, as this may not be possible in late stages of muscular dystrophy, passive lengthening
would be the optimal treatment. With passive lengthening, the joint must be slowly moved to the
maximum tolerated range and held for a prolonged period of time to desensitize the stretch
receptors. Ballistic or rapid maneuvers with the intention of removing adhesions are
contraindicated. To affect muscle physiology, viscoelastic accommodation of the muscle has
been shown at 90 seconds, to result in a stress relaxation response to stretching.117 Additionally,
in view of the viscoelastic response, early stretching would be beneficial in younger individuals
because their muscles are more pliable to maintain extensibility. For maximum impact of change
in the muscle physiology and stretch tolerance, a stretch of 90 seconds or more is recommended.
Daily passive and active range is recommended to counter complications that may arise in
muscles and joints from muscle imbalances and immobilization, along with possible downstream
influences on cellular and biomechanical processes of tissue repair.174 Immobilization may lead
to chemical changes consistent with osteoarthritis,175 dysfunction of extra-articular tissue
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alignment176, 177 and degradation of collagen mass that may be further complicated by
inflammation or fibrosis typically seen in many NMD, thus inhibiting normal joint gliding
motion.178
Two systematic reviews have provided evidence that manual stretching of the
hamstrings153 and gastrocnemius/soleus 179 increase joint range of motion, while other studies
support evidence of improved range with stretching but no evidence of long-term changes in
muscle extensibility.164, 165, 180, 181 The studies reviewed included otherwise healthy individuals
with limitations in joint range of motion. While these results are promising, individuals with
pathological changes in the structure and function of their muscle, such as those with
neuromuscular disease, are unlikely to respond to stretch in a similar way.
Two further systematic reviews have investigated stretching interventions for individuals
with neuromuscular10 and other neurological disorders.153 One systematic review specifically
investigated interventions for increasing ankle range of motion in patients with neuromuscular
disease.10 Although stretching interventions aiming to improve ankle dorsiflexion range of
motion are widely employed for patients with neuromuscular disease, only four studies involving
149 patients met inclusion criteria for the review. This review included three studies
investigating stretching interventions for patients with neuromuscular disorders, and it is highly
likely that stretching interventions of greater intensity and duration would be required to achieve
results similar to those seen in the otherwise healthy individuals with restricted joint range.
Stretching: Long Duration
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Long-duration stretching consists of wearing custom-made ankle foot orthoses (AFOs),
also referred to as orthoses. These are prescribed to be worn for 6+ hours.7, 14
At initial diagnosis, AFOs are generally prescribed for night wear. AFOs worn at night are
not well tolerated by some individuals, with complaints of the device being heavy and resulting
in the inability to move in bed or walk to the bathroom. Some individuals wear AFOs while
awake but participating in seated activities. With increased use of a wheelchair, AFOs can be
worn during the day or night. Self-reported wear duration varies widely. Some biomechanical
limitations to AFOs include, 1) AFOs do not address foot inversion contracture; 2) AFOs do not
adequately target Achilles for stretch; and 3) Pressure sores commonly arise with growth and
contracture progression.
Animal studies support management of contractures with long duration stretching.178, 182, 183
These studies have shown that, although both dystrophic and denervated muscle fibers are
diseased, they are capable of adding sarcomeres in series when immobilized in a lengthened
position. The major difference between diseased muscle and unaffected muscle is that addition of
sarcomeres occurs at a slower rate.184 It is also likely that response to stretching interventions
differs depending on the type of neuromuscular disorder. While similarities in muscle
morphology are seen in some disorders, the response to stretching interventions may be better in
some disorders than others. For example, dystrophic muscle, as seen in DMD, is characterized by
a high percentage of fat and scar tissue that increases with disease progression.185 Collagen,
which comprises a large portion of scar tissue, has a greater modulus of stiffness than muscle, so
that muscle with scar tissue has reduced extensibility, requiring greater force to stretch it.154 By
comparison, muscle in Charcot-Marie-Tooth (CMT) disease is characterized by fatty infiltration
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of selectively denervated muscles.185, 186 While some scar tissue is present, it is not as abundant
as seen in DMD, which might indicate that individuals with CMT may respond better to stretch
and require a stretch of a lesser intensity and duration than patients with DMD. A systematic
review of neurological conditions including traumatic brain injury, cerebral palsy, and stroke
noted moderate evidence of short term effect of joint mobility and no effect on functional
activities.187
Long-duration stretches are defined as anything greater than 30 minutes. There are
numerous ways to perform a long-duration stretch: Positioning, hand splints, standing frames,
serial casting, Ankle-Foot Orthoses (AFO) or Knee-Ankle-Foot Orthoses (KAFO). There are 2
general types of AFOs: 1. Static (hold ankle in one position) 2. Dynamic (hinged joint which
provides added stretch). The static AFO maintains the current ROM, while the dynamic AFO has
the ability to provide added force for a more intensive stretch. Most studies have assessed static
nighttime splints. Two studies investigated night splinting for patients with CMT188 and the other
investigated serial casting at night189 for patients with CMT. A small, randomized comparative
study of patients with DMD found that strength was a significant variable in determining the
degree of contractures and concluded that individuals who both performed manual stretches and
wore night-time splints had 23% less chance of developing contractures compared to stretching
alone.190 Hyde et al190 and Seeger et al191 found a decrease in plantarflexion contractures with the
use of night time orthoses, while Brooke, et. al192 did not find any differences with night time
orthoses. Possible explanations for the differences would be small sample sizes and methodology
in assessing contractures. Most of these studies measured ROM with a goniometer, without
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standard force applied to the measurement. As elastic deformation of soft tissue is directly
proportional to stretch velocity and force of application. Long-duration stretches are defined as
anything greater than 30 minutes. There are numerous ways to perform a long-duration stretch:
Positioning, hand splints, standing frames, serial casting, Ankle-Foot Orthoses (AFO) or KneeAnkle-Foot Orthoses (KAFO). There are 2 general types of AFOs: 1) static (hold ankle in one
position) and 2) dynamic (hinged joint which provides added stretch). The static AFO maintains
the current ROM, while the dynamic AFO has the ability to provide added force for a more
intensive stretch. Most studies have assessed static nighttime orthosis. Two studies investigated
night splinting for patients with CMT188 and another investigated serial night casting189 for
patients with CMT. A small, randomized comparative study of patients with DMD found that
strength was a significant variable in determining the degree of contractures and concluded that
individuals who both performed manual stretches and wore night-time orthosis had 23% less
chance of developing contractures compared to stretching alone.190 Hyde, et. al190 and Seeger, et.
al.191 found a decrease in plantarflexion contractures with the use of night time orthoses while
Brooke, et. al192 did not find any differences with night time orthoses Possible explanations for
the differences would be small sample sizes and methodology in assessing contractures. Most of
these studies measured ROM with a goniometer, without standard force applied to the
measurement. As elastic deformation of soft tissue is directly proportional to stretch velocity
and force of application,193, 194 the amount of force placed on the limb by the evaluator could
vary in each of these studies.
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Other orthoses that can be used for stretching and weight-bearing are KAFOs. KAFOs
have been used in DMD195 studies for upright stretching of the lower extremities and assisted
gait. Considerations for KAFOs should focus on lightweight polypropylene material, droplocked knee joints, solid neutral ankle and ischial weight-bearing bearing. Ischial height is
important for appropriate trunk support and upright positioning. Additionally, patients must have
some truncal strength in order to use KAFOs. Many of these studies did not focus on ROM and
only noted minimal to poor evidence for the use of KAFOs196 in DMD, but a few case studies in
SMA have found that early fitting of KAFOs proved beneficial for gait.197 KAFOs are not
normally recommended for ambulation due to safety concerns and the increased energy cost
associated with walking in heavy KAFOs.
Serial casting is another method that may improve range of motion. This is typically done
for ankle contractures. Considerations include the negative effect of the weight of the cast on
function, atrophy due to immobilization, and tolerance. Serial casting has been studied in
DMD,187, 198, 199 but a serial casting , with a mean of 12 degrees improvement in range of motion,
but without effects on timed function tests.187 Main198 also found that a serial casting procedure
showed reduction in contractures but associated with mental distress. A study of serial casting in
CMT showed a mean improvement of 4 degrees with improvement on time tests.189 Serial
casting may be considered for patients with DMD with careful consideration of biomechanics,
strength, and functional status of the patient. A study of serial casting in CMT showed a mean
improvement of 4 degrees with improvement on time tests.189 Serial casting may be considered
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for patients with DMD with careful consideration of biomechanics, strength and the functional
status of the patient.
STANDARDS OF CARE
Management of individuals with DMD greatly varies based on geographical location (CDC
expert panel, 2005). Medical care largely varies around the world with most variations associated
with medical equipment, frequency of visits, physical/occupational therapy, and psychological
care. 53 Identifying and optimally managing secondary conditions in a comprehensive and
consistent manner is key for the provision of quality care.21, 25 With the promising therapeutic
development pipeline in DMD, there needs to be consistency in SOC. The development of the
SOC guideline was an international initiative led by the CDC of key stakeholders including
patients, clinicians, government agencies, scientists, health agencies, and patient advocacy
groups including the Parent Project Muscular dystrophy, Muscular Dystrophy Association and
Treat-NMD.21 Optimizing SOC is now a necessary initiative to support clinical trials readiness in
DMD.
In 2010, the CDC published a 2-part series on DMD Care guidelines and management.21, 25
which highlighted the need for an interdisciplinary approach and coordination of care among
subspecialties to provide appropriate management of this multi-systemic disease. This document
involved over 80 clinicians and patient advocates and highlighted primary and secondary
manifestations of DMD that require management, with sections on neurology, steroids,
cardiology, pulmonology, physical therapy/physical medicine and rehabilitation, orthopedics,
surgical considerations and psychosocial care (Figure1). Care recommendations were based on
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the 5 stages of DMD: pre-symptomatic, early ambulatory, late ambulatory, early non-ambulatory
and late non-ambulatory.21, 25, 42, 43 With the changing landscape of DMD and a paradigm shift to
a more anticipatory and prevention-based model of practice, the original CDC Care Guidelines
were updated in 2018.42, 43 A steering committee of clinicians published a 3-part care
considerations document with the goal to increase survival and guide care interventions with
consideration of emerging molecular and genetic treatments in DMD. Three additional topics
were added from the original 8 in the 2010 guidelines including primary care and emergency
management, endocrine, and transitional care across the lifespan.42, 43
As part of the guidelines’ recommendations, GC therapy should be assessed on the course of
motor abilities, (ie: progress, plateau, or decline phase). The decision to start GC should be based
on the family’s report and using a team approach to care management. After start of GC, the
physician must closely monitor for side effects, and motor skills should be assessed by physical
therapist.21, 43
Standards of care suggest that “assessment and anticipatory management must be provided
across all domains of the International Classification of Functioning, Disability and Healthy
(ICF) model” starting from the time of diagnosis.43 Contracture management was noted as a
primary focus of treatment in DMD with emphasis on short duration stretches 4-6x/week,25, 43
and on long-duration stretching with Ankle Foot Orthoses (AFO) for night time or day time wear
in those who are non-ambulant.25, 43 Musculoskeletal assessments should be performed by an
experienced clinician who understands the DMD disease course and how to monitor disease state
through strength testing, range of motion measurements, observational gait analysis, and
52

established timed function tests.42
A 2010 Cochrane review of interventions to increase ankle range of motion in neuromuscular
diseases concluded that the quality of evidence for interventions to increase ankle range of
motion, such as stretching and bracing, was low and further research is required.10 Currently, in
DMD there is lack of evidence on the effects of short or long duration stretching on dystrophic
muscle, however, this does not negate the benefits for individuals who have muscle imbalances
or weakness that prevents active joint movement, as stretching can result in enhanced joint
lubrication, enhanced circulation, and overall decreased tightness. Expert consensus among
physical therapists continues to support the use of stretching and night time braces for
management of contractures.25, 43, 200
DRUG DEVELOPMENT IN DMD

As we better understand the pathophysiology of dystrophin deficiency in different body
organs and gain a better understanding of the natural history of DMD, the treatment options
appear to be multifaceted. While there has not been a cure for this disease, treatment has been
focused on supportive therapies of impairment-based difficulties, such as the weakness and
contractures associated with disease manifestation.
With the changing SOC to improve the quality of life for boys with DMD, there has been
an evolution in structured natural history studies to better understand this changing phenotype and
its impact on function (Figure 3) Corticosteroids as a standard of care recommendation in DMD
resulted in a slowing of disease progression as evidenced by boys maintaining the ability to
ambulate longer than in the pre-steroid era. One of the fundamental barriers in DMD research that
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has been identified is the lack of detailed understanding of the characteristics and natural history
of DMD. To address this gap, CINRG developed one the longest natural history studies performed
in neuromuscular disease. CINRG developed the first multicenter international clinical trial system
for DMD since the dissolution of the MDA-funded Clinical Investigation of Duchenne Dystrophy
(CIDD) over 15 years ago. The design of the CINRG DMD natural history study is based on
previous developments in clinical outcomes and an ICF-based evaluation model to better
understand the DMD phenotype in the age of steroids. Clinical outcome measures used in this
natural history study are now currently used as primary and/or secondary endpoints in large
therapeutic clinical trials from the pharmaceutical industry. From a clinical perspective, the
strength and functional assessments used in this study are now providing insight on disease
progression to help with care management and planning. Ideal clinical endpoints for future clinical
trials must be sensitive to show the magnitude of disease-related changes, and clinically
meaningful in regards to their impact on boys with DMD and key milestones such as loss of
ambulation.
FIGURE 3 EVOLUTION OF DMD NATURAL HISTORY STUDIES
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Since dystrophin is not only located in skeletal muscle, there are many potential targets in
the drug development pipeline for DMD. Compared to 30 years ago, when there were only
natural history studies; there are currently 41 drugs being developed or tested for DMD.201 As is
typical in drug development, many drugs have shown great promise in early-stage pre-clinical
development, but then failed to show efficacy in clinical trials. The research presented in this
dissertation are relevant to drug development as many of the clinical outcomes used in trials for
boys with DMD include strength measures and timed function tests. Additionally, ROM and
velocity measures of the timed function tests have also been used as inclusion/exclusion criteria
to ensure homogenous populations in studies and decrease the risk of attrition from an individual
with DMD losing ambulation during a clinical trial. Because of the extensive scope of discussing
potential therapies for DMD, this section will focus on later-stage therapeutic targets associated
with current novel gene therapies of exon skipping for DMD and downstream targets affecting
skeletal muscle strength and function and fibrosis.
Exon Skipping Therapies
The most novel of the therapeutic approaches is restoration of dystrophin, a mutationspecific gene therapy approach. The severity of the disease is based on mutations on the DMD
gene, which codes for the dystrophin protein. To understand exon skipping, we will broadly
address the genetic defect of dystrophin deficiency in DMD. There are over 7,000 different
mutations in the dystrophin gene.202 These mutations tend to be out of the reading frame, and
may be small or large deletions that result in a non-dysfunctional dystrophin protein. As
discussed earlier, dystrophin attaches the cytoskeleton to the extracellular matrix and is essential
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in sarcolemma stability. Some in-frame mutations that maintain a partial reading frame will
result in a dysfunctional or partially truncated dystrophin, protein meaning that some dystrophin
is produced. In-frame deletions or duplications result in a less severe form of DMD called
Becker muscular dystrophy (BMD). Currently eteplirsen, a treatment specifically targeting exon
51 which applies to approximately 13% of the population, has received accelerated approval
from the FDA in 2016.203 By skipping exon 51 which contains the mutation, the drug produces a
truncated dystrophin protein that may result in some clinical benefit. Ataluren is another
treatment targeting non-sense mutations in the dystrophin gene with the purpose of increasing
expression of full-length dystrophin and was one of the first trials in DMD. It currently has
approval by the EMA based on sufficient clinical data based on a biomarker outcome of increase
in dystrophin production yet did not meet the primary study endpoint of significant increase in
the 6MWT204 resulting in the FDA declining its approval in 2016.
Corticosteroids and Nuclear Factor the NF-Kappa B Pathway
Currently, an anti-inflammatory GC is the only widely accepted therapeutic intervention
to maintain strength and function for boys with DMD. Even though the exact mechanism of
action of GCs in DMD is not fully known, these drugs are thought to inhibit the NF-Kappa B
pathway. 32, 205 Due to the enormous problems with long-term use of GCs, a GC analog,
vamorolone, has been developed by ReveraGen BioPharma. Pre-clinical trials in MDX mice have
shown decreased side effects from this drug, such as a lack of stunted growth and
immunotoxicities that are traditionally associated with standard GCs.206 In the drug development
process has ReverGen has successfully completed a phase 1 safety and tolerability study, and is
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currently enrolling in a phase 2b pivotal trial, placebo controlled with a prednisone arm. Other
pharmacological approaches to inhibiting the NF-Kappa B pathway, have also been explored by
Catabasis. Their compound CAT-1004 (edasalonexent) showed a reduction of muscle
degeneration and improved regeneration in both skeletal and cardiac muscle in MDX mice. They
have successfully completed phase 1 studies showing significant decreases in NF-Kappa B
activity207 and phase 1/2 clinical trial in young boys ages 4-7 with DMD.
(https://clinicaltrials.gov/ct2/show/NCT02439216)).
Increasing Muscle Mass
There are a few different approaches to increasing muscle mass in DMD, which have
been studied in MDX mouse models and are slowly moving into the clinical space. Due to the
loss of muscle mass as a result of fiber degeneration and decreased regeneration capabilities,
increasing muscle mass seems to be a logical approach.
Myostatin Inhibitors
Myostatin inhibition is the furthest developed strategy for increasing muscle mass.
Myostatin is part of the transforming growth factor-beta (TGF-Beta) family that regulates
skeletal muscle growth. The exact mechanism of action is not completely understood, but it is
believed to suppress precursor muscle differentiation cells through the Mstn regulatory gene.208
Animals who have the Mstn gene knocked down have been found to show extremely
hypertrophied muscles. Studies specific to dystrophic muscles have been performed in MDX
mice indicating that anti-myostatin may increase muscle mass by >35% from muscle fiber
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enlargement with decreased creatine kinase levels. When studied in larger animal models, such
as the dystrophin-deficient golden retriever dog, this approach they showed negative effects of
unequal muscle growth and increased development of joint contractures.209 However, clinical
trials have been initiated due to the promising results from the MDX trials. Recently, Pfizer
ended a 2 year study of domagrozumab in boys with DMD early due to the inability to
demonstrate efficacy with their primary endpoint of stair climb after one year of treatment.210
Another study involving the drug MYO-029 was also terminated due to the inability to show
increases in muscle strength or function for adults with Becker Muscular Dystrophy (BMD),
Limb Girdle Muscular Dystrophy (LGMD), and for Fascioscapulo Humeral Dystrophy (FSHD).
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More recently, the myostatin inhibitor that was developed by Bristol-Meyers Squibb and

licensed to Roche had a phase 2/3 clinical trial to evaluate the safety, efficacy and tolerability of
RO7239361 in ambulatory boys ages 6-11 years but terminated due to the study not meeting its
clinical endpoint.212
Anti-Fibrotics to address Fibrosis
In a disease such as DMD where muscle degeneration is replaced by connective tissue
and fibrosis, a primary therapeutic target would be to address fibrosis. The extracellular matrix is
a crucial component to healthy muscle by providing the necessary scaffolding for tissue repair
and growth. The downstream effects of dystrophin loss result in fragility of the sarcolemma,
muscle fiber degeneration, and increased activation of profibrotic signaling pathways so that
muscle tissue is replaced by adipose and connective tissue. Muscle tissue is much more pliable
and has more extensibility compared to the more rigid fibrotic tissue. As previously mentioned,
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TGF-Beta is important in muscle growth but also in regenerating fibers after tissue injury with
the expression of profibrogenic factors.213, 214 Tissue damage initiates a transcription of
profibrotic genes such as fibronectin and collagen, resulting in degradation of the extracellular
matrix. Studies have found that TGF-Beta levels correlate to muscle fibrosis in boys with
DMD.215 The hypothesis is that targeting the TGF-Beta pathway may increase muscle
regeneration, thus reducing fibrosis in DMD.
A well-known TGF-Beta inhibitor, Losartan, has been studied in MDX mice and in a
small clinical trial. It blocks the angiotensin-II receptor that is required for appropriate TGF-Beta
signaling.216Mice studies showed increased grip strength and decreased fibrosis of the diaphragm
and cardiac muscle.217, 218 Human trials showed that it improved cardiac ejection fraction with a
good safety profile.219
Other more recent trials of anti TGF-Beta drugs include Halofuginone (HT-100), an antifibrotic that inhibits collagen synthesis by preventing SMAD-3 from binding to DNA to control
the activity of specific genes.220 The results for this study were promising, with more than 10%
increase in muscle strength and signs of increased collagen degradation, however the FDA put
the study on hold after a patient died. Currently, the FDA has provided clearance for Akashi to
resume enrollment in the study.221
CLINICAL ENDPOINTS USED IN CLINICAL TRIALS
Clinical Endpoints used in Clinical Trials Based on the framework of the WHO ICF,222 there
are 4 domains that impact activity including body function and structure, participation, and
environmental factors. Data collection for clinical outcomes in the natural history of DMD has
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been based on this framework to promote patient center care and clinical outcomes
assessment.223 The ICF model and disablement models facilitates a common language towards
clinical research that is patient centered and disease specific. This approach promotes alignment
of clinical outcomes to disease related outcomes where the dimensions of the model coincides
with the level of disablement related to DMD (Figure 4).41, 224, 225
FIGURE 4: DISABLEMENT DIMENSIONS AND LEVELS
WHO Disablement
Model

Pathology:
Cellular
Impairment:
Body systems
Functional
LImitations:
Whole person
Disability:
Relation to
Society

ICF Model

DMD

Health Condition
Body Structure &
Function

Lack of Dystrophin, Fibrosis

-Decreased strength (Knee Strength)
-Contracture Development (Ankle ROM)

Activity (limitation)
Effects on Timed Function Tets:
Supine to stand, Stairs, 10mwt

Participation
(restriction)

Participation in obtaining a job,
access to community, school

Physical therapy evaluations have focused on understanding the effect of body
functions/structures (strength and range of motion impairments) on activity (functional
limitations), and their association with mobility and participation. These functional limitations
have been reported by clinicians and families as important but limited published data relating it
to patient reported outcomes (PROs). Additionally, there continues to be minimal information on
losses related to socio-economic costs and quality of life.
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In August 2005, the NIH-led Muscular Dystrophy Coordinating Committee (MDCC)
established by congressional mandate identified a number of research priorities for muscular
dystrophies which included 1) natural history studies in specific conditions; 2) determination of
the sensitivity of clinical endpoints to changes in disease severity; 3) determination of the
magnitude of changes in endpoints which are clinically meaningful to patients; 4) study of the
interrelationship of clinical endpoints for specific muscular dystrophies; 5) development of
standardized data collection and a minimum data set for multicenter data gathering; and 6)
identification and development of standardized instruments to measure quality of life.
In 2006, at a National Institute on Disability and Rehabilitation Research (NIDRR) meeting
to discuss challenges in muscle disease, the FDA specified that clinical trials conducted in
support of new drug approvals or revised indications for already approved drugs must
incorporate a primary endpoint that objectively measures a clinically meaningful “life-changing”
milestone that has a significant impact on a patient’s perceived overall health and well-being.31
In DMD, these functional milestones have been used to stage or describe 5 different
significant stages of DMD (Figure 1).5, 21, 22 With better understanding of the sequential loss of
function, clinicians were able to define stages of the disease based on functional level. As
previously described, supine to stand, 10MWT test, and 4-stair climb tests have frequently been
used in both the clinic and research to understand and predict disease progression. These clinical
outcomes are used in clinic for a proactive approach to clinical care utilizing predictive modeling
for losses of function, while clinical trials utilize it in a similar manner to reduce attrition rates in
trials from patients losing the ability to perform a clinical measure. For example, as part of
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inclusion criteria, studies may assess ankle range of motion and some timed function tests to
evaluate function, as timed measures have been good predictors of loss of function. This
information helps manage possible attrition in clinical trials from patients losing function that
may impact a primary endpoint chosen for the study. Ankle range of motion is thought to play a
factor in the ability to perform these timed tests, but no studies have looked into its contribution.
Researchers have also evaluated timed tests and their association with patient-reported
outcome measures to show impact on quality of life and perception of abilities. McDonald et al
(2010)39 first showed significant correlations in boys with DMD of the Pediatric Outcomes Data
Collection Instrument (PODCI) and the Pediatric Quality of Life Inventory (PEDSQL) with age
and timed functional tests such as 10-meter run/walk, supine to stand, and stair climb. This study
was pivotal in proving construct validity with a parent-reported health-related quality of life
measure and functional measures.39 The study team found that the PODCI domains
mobility/transfers and sports/physical function best correlated with age, knee strength, and timed
tests;39 linking these activity-based measurements to significant changes in the perception of
function. Additionally, clinicians have debated over the role of contractures in the ability to
perform some of these “life-changing” milestones. Biomechanically, we know that muscle force
production and biomechanical demands change based on the alignment of the musculoskeletal
structures and progressive strength loss.
Following the FDA’s request for better understanding of the relationship between timed
function tests and patient-reported outcomes, in 2009 the European Medicines Agency (EMA)
provided a directive for the international DMD community to create consensus and guidance for
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age-appropriate clinical outcome measures that may be used in multi-site international trials.226
In response to this request, an international clinical outcomes working group was assembled in
2010 consisting of 25 leading experts across Europe and the United States, with the aim to
discuss current available natural history data that may help determine consensus based on the
robust and valid measures being used around the world. In order to come to a consensus, the
group reviewed large datasets and determined gaps in the understanding of the longitudinal
clinical picture of boys with DMD. The international group found that the functional outcomes
used to assess boys who are ambulatory were psychometrically sound and valid to be used in
large multi-site clinical trials. Despite this they found a huge gap in the amount of quality
outcome measures that encompass the spectrum of the disease, particularly for boys who are
non-ambulatory.22 Most treatments for DMD focus on boys who have more preserved muscle
function, meaning that they will most likely be ambulatory. The meeting results included 1)
identification of gaps in the current literature for individuals with DMD, including a need for an
upper limb measure that may be assessed throughout the spectrum of the disease; 2) a significant
understanding of the steroid-era natural history of the disease; 3) psychometric properties
required for clinical outcomes that may be used in clinical trials; and 4) establishment of focused
working groups to address needs that arose from this meeting. A subgroup of international
physical therapists and a few physicians later developed an upper limb tool called the
Performance of Upper Limb Scale for DMD 227 and established a framework for inclusion of
clinical outcomes in clinical trials (Table 2). This table also outlines how well DMD clinical
outcome measures meet the necessary psychometric criteria to be a valid assessment in DMD.

63

TABLE2: INCLUSION OF CLINICAL OUTCOMES CRITERIA
Properties for Clinical Outcomes
Evaluation

Clinical subgroups

Timed Function
Tests (10MWT,
supine to stand, 4
Stair Climb)

4 years until nonambulatory

Supports mechanism of action of
Drug being studied
Conceptual framework

✔

Strength
(Quantitative)

PROs-PROM

Lower
Extremity=5-12
years

7-20+ years

Upper
Extremity=5-20+
years
✔

✔

✔

✔

✔

Reliability

✔

✔

✔

Validation with other measures

✔

✔

In progress

Normative ranges

✔

In progress

In progress

✔

✔

✔

Multicenter studies

✔

✔

✔

Responsiveness to treatment

✔

✔ (more research
required)

✔

✔ (more research for
MDC/MCID)

x

✔

fits DMD

Ongoing natural history studies

Clinical meaningfulness
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These discussions brought forth a gap in the knowledge regarding the understanding of
minimal clinically important differences of these measures, so it was difficult to understand the
meaning behind raw scores of these timed tests, and their relevance to clinical change.
Functional losses or delays in losses have historically been equated to clinical meaningful change
in boys with DMD, which also contributed to disease staging.5, 21, 22 For diseases that are chronic,
progressive and variable in clinical presentation, a deep understanding of the variables that
contribute to inconsistency is crucial for appropriate medical management71. Parents have
reported that loss of ambulation, the ability to get up from the ground, or to climb stairs re
significant factors impacting family quality of life and reported perceptions of disability (PPMD,
Washington DC, Annual Connect Meeting, 2015). This may be due to parents being well-versed
in the science of the disease and understanding that prolonged time needed to complete these
measures would be an indicator of disease progression.
MINIMAL CLINICALLY IMPORTANT DIFFERENCE
With the growing number of clinical trials in DMD and rising healthcare costs for
treatments, there is a need for clinicians to use clinical measures to predict a patient’s response to
treatment in order to help guide clinical decision-making for anticipatory care management. With
the physical therapy profession moving towards evidence-based practice, there’s a need for
outcome measures to help inform clinical planning, decision-making, and care management,
especially in chronic and progressive disease. In parallel to treatment trials for DMD,
academicians are also studying the possible genetic associations with single nucleotide
polymorphisms (SNPS) that may predict functional decline146, 228 or response to treatment. The
timed function tests that were analyzed in this study have been reported to have sound
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psychometric properties of reliability and validity, as well as good predictive qualities. These
properties give assurance that changes in these clinical endpoints are less likely to be due to
measurement error. However, there needs to be a better understanding of the impact of change in
the timed function tests to patients’ quality of life. This is where MCID measures become
important to provide the patient/clinical perspective to these outcome measures. MCID is
typically defined as a minimal change that is significant to a patient.46 MCID measures are not
only important to patients, but they provide clinicians with a critical value that corresponds to a
measurable change helping determine clinical goals and disease monitoring to improve
anticipatory care management. It is also increasingly important to payers, as they are the ones
defining approval or payment for therapies based on published MCID outcome reports making it
essential for researchers to accurately report measures that are specific to the particular patient
population.
Anchor-based and distribution-based methods to provide meaningful estimates of MCID
for outcome measures are increasingly employed in disease-based treatment development
research.229-232 In the anchor-based approach, the meaningfulness of the change in a study
measurement is determined based on the ability of a change score to predict the occurrence of a
clinically meaningful milestone in the natural history of the disease.232, 233 MCID is the minimal
amount of change to a clinical outcome that may make a difference in clinical care or quality of
life to a patient.63, 234 MDC also has been used to describe as true change that is not attributed to
error or variability. MDC is a statistical approach based on distribution-based methods and not
anchored to clinical significance.63 MDC is calculated based on the standard error of the mean
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(SEM) of the clinical outcome being used to determine minimal change. Statistical change does
not necessarily translate to clinical benefits.
Researchers have used both distribution-based and anchor-based methods to determine
MCID. Distribution-based methods depend on statistical approaches based on psychometric
soundness of a clinical outcome, without reference to a clinical or patient perspective of change.
Anchor-based approaches use clinical or patient interpretation to understand the magnitude of
change and is typically are compared with other clinical measures.71 A lack of consensus on
determining and defining MCID measures has caused confusion in interpretations of their
meaning. MCID approaches consist of a variety of methods including clinician consensus
approaches, psychometric-based, distribution, and anchor-based approaches.63 On a document
about patient-reported outcomes, the FDA attempted to provide guidance on interpretation and
implications of MCID measures.235 However, due to lack of consensus, MCID was defined as
the smallest difference in outcomes that may be proxies of perceived importance to patients.235
With little guidance, clinical trials continue to report MDC measures of change, which may
under or overestimate the clinically important differences or significance of results. This
becomes a problem as payers tend to require clinical outcomes used in trials as a minimal
criterion for payment. Non-anchored based MDC may not be the best method to determine
importance of a clinical outcome measure, as a whole.
In describing change, there are multiple stakeholders indicated by the range in methods of
determining MCID. These stakeholders include clinicians, patients, researchers, pharmaceutical
industry, and payers. Determining MCID in clinical trials is crucial as it determines the minimal
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criteria that will be required for payers and used by clinicians to assess change. In describing
change, literature looks at functional status, health status, and health-related quality of life
(HRQOL). Patient’s perception of change is usually described as health status or HRQOL, while
functional status change is based on performance of a physical measure.71
To improve the applicability of MCID measures to a specific disease or patient
population, the method of recruitment of patients used in determining MCID measures must be
considered.236 Another factor to consider is the use of cross-sectional or longitudinal data to
determine MCID. Cross-sectional approaches compare different groups based on a diseaserelated criteria, such as ambulatory status, at a given single time point, whereas longitudinal
methods use an anchor-based approach to establish a meaningful change over time.71
Longitudinal methods are commonly used in clinical trials, including DMD studies. This
highlights the many different definitions of MCID used to describe changes in a clinical
outcome. Accurate interpretation of MCID for ambulatory boys with DMD must use the same
methodologies from clinical trial recruitment, such as the definitions for inclusion/exclusion
criteria. With the variability in phenotype in boys with DMD, this study focused on a range of
MCID scores for more of a population-based approach to determining MCID rather than a single
value that is more patient-focused.237 In order to do this, construct validity was established
between the 3 timed function tests, strength, and range of motion. Understanding the
relationship between these measures leads to better interpretability of the MCID values presented
for ambulatory boys with DMD.
Understanding and determining MCID values for these commonly used assessments in
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DMD may greatly impact the interpretation of functional changes commonly used in the clinic,
such as the 10MWT, supine to stand and stair climb. This provides a better understanding of the
current natural history of DMD and better predict loss of function for improved planning to
obtain appropriate assistive devices that promote independence and decrease caregiver burden.
Additionally, MCID values assist in determining sample sizes when designing clinical trials for
better interpretation of clinical outcomes and relevance.48
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CHAPTER 3: METHODOLOGY
RESEARCH DESIGN AND METHODOLOGY STUDY DESIGN
Data was collected retrospectively from the largest longitudinal natural history study of
boys with DMD. This study was performed by CINRG, a consortium of 26 clinical sites around
the world with the primary goal of better characterizing and understanding the pathophysiology
and clinical presentation of neuromuscular diseases, and of contributing to improved clinical
outcomes that are relevant to daily functional activities and quality of life (www.
Cinrgresearch.org). The DMD Natural History study has evolved over a 10-year period. Data
collected in this study included a long list of clinical outcomes developed based on the WHOICF
model41. Data was collected for basic anthropometric measurements (height, weight,
goniometric range of motion, ulna and tibial length), functional assessments (MMT and QMT,
10MWT, Supine to stand time, 4 stair climb time, Northstar Ambulatory Assessment), quality of
life PODCI, PedsQL, Short Form Health Survey (SF36), Neuro Quality of Life Measure
(NeuroQOL) measures, and surveys on access and use of interventions used by the DMD
community.
The relationship between contractures, strength, and functional mobility was evaluated
using data from this study. Gait speed has been reported to be a good clinical predictor of loss of
ambulation in individuals with DMD.5, 10 Data from this study was used to estimate MCID values
for 10MWT, supine to stand, and 4 stair climb anchored to the Vignos lower extremity scale.
The 3 timed tests are commonly used to measure function in boys with DMD. The Vignos Lower
extremity scale (Figure 5) is an ordinal scale used to describe lower extremity functional ability
in boys with DMD. Any changes in the Vignos scale would reflect clinically meaningful
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functional loss of either walking, getting out of a chair, or the ability to climb stairs. These
changes in the Vignos typically triggers clinical needs for assistive devices and accommodations
at school or home. Rate of change was analyzed per timed function tests based on a change in the
Vignos scale.
FIGURE 5: VIGNOS LOWER EXTREMITY SCALE

1. Walks and climbs stairs without assistance

2. Walks and climbs stairs with aid of railing
3. Walks and climbs stairs slowly with aid of railing (over 12 seconds for 4 standard stairs)

4. Walks unassisted and rises from chair but cannot climb stairs.
5. Walks unassisted but cannot rise from chair or climb stairs.
6. Walks only with assistance.
7. Participant is dependent on wheelchair for all mobility.
8. Participant is in bed at all times.
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INCLUSION/EXCLUSION CRITERIA
Since this was a natural history study, it included anyone who was genetically and/or
phenotypically diagnosed with DMD. The inclusion and exclusion criteria were meant to ensure a
homogenous population of only individuals who have DMD and not the milder type of BMD.
Table 2 lists the inclusion/exclusion criteria for the study. Inclusion criteria for this analysis
included all inclusion criteria from the original CINRG natural history study and patients who
were able to complete all clinical outcomes that are part of the analysis including: QMT knee
strength, Ankle ROM, 10MWT, Supine to stand, 4 stair climb and Vignos LE scale.
TABLE 2: CINRG INCLUSION/EXCLUSION CRITERIA
Inclusion Criteria
•
•

•

Patients must be male between the ages of 2 and 30
Affected patients between the ages of 2 and 4 must have a diagnosis of DMD
confirmed by at least one the following OR have an older male sibling that meet at
least one of the following criteria:
o Dystrophin immunofluorescence and/or immunoblot showing complete
dystrophin deficiency, and clinical picture consistent with typical Duchenne
dystrophy OR
o Gene deletion test positive (missing one or more exons) in the central rod
domain (exons 25-60) of dystrophin, where reading frame can be predicted
as 'out-of-frame', and clinical picture consistent with typical Duchenne
dystrophy.
o Complete dystrophin gene sequencing showing an alteration (point
mutation, duplication, other) that is expected to preclude production of the
dystrophin protein (i.e. nonsense mutation, deletion/duplication leading to
a downstream stop codon), with a typical clinical picture of DMD.
Affected patients between the ages of 5 and 30 must either fulfill the above criteria
OR show evidence of a dystrophinopathy and clinical picture consistent with
Duchenne Muscular Dystrophy
o Patients who have documented clinical symptoms referable to a
dystrophinopathy and direct support of the diagnosis by either (1) a positive
DNA analysis for dystrophin mutation, (2) a muscle biopsy demonstrating
abnormal dystrophin, or (3) an elevated CK (>5X normal), and X-linked
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pedigree and an affected family member who meets either criterion (1) or
(2) as described above.
NOTE: Determination of the appropriate clinical symptoms consistent with
DMD will generally be the responsibility of the clinician. At a minimum this
will include progressive loss of function, with additional consideration for other
clinical features such as a characteristic gait, a positive Gower’s sign and calf
pseudohypertrophy. When immunostaining of muscle biopsy is used to
determining case definition, the clinical reviewer (site PI) should confirm that
appropriate testing has ruled out a secondary deficiency of dystrophin.
Affected patients that do not exhibit the above symptoms consistent with DMD
should be excluded.
o Muscle weakness prevalent by 5 years of age
•

Non-affected adult patients must be Parent(s) or legal guardian(s) of an eligible
affected subject.
Exclusion Criteria

For those patients that confirm DMD diagnosis through a clinical picture consistent with DMD
•

Steroid-naïve patients ambulating past the 13th birthday

•

Steroid users ambulating past the 16th birthday

•

Patients/families who are unwilling or unable to comply with the protocol study
procedures or visits

Recruiting Procedures
Individuals participating in this DMD natural history study were a sample of convenience
who were identified at the 26 international and national clinical sites by the neurologist or
individuals from the clinical or research team at each institution. Methods of recruitment were by
word of mouth, the website www.clinicaltrials.gov., and internet or other means of IRB-approved
advertisement from their respective institutions.
Specific Procedures
DATA COLLECTION AND MANAGEMENT PROCEDURES
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Clinical endpoints used in this study were all collected by licensed physical therapists
who received annual certification from CINRG to ensure standardization of procedures (Table
3). Details of study procedures for the study are included as part of the CQMS User’s Manual
Appendix. Clinical assessments were performed most frequently in the first year with 5 visits; 2
visits in the second year followed by annual visits (Figure 6)
FIGURE 6: STUDY VISITS

Visit Frequency
Year 1
Baseline

Month 3

Month 6

Month 9

Year 3

Year 2
Month 18

Month 12
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Month 24

Annual
Visits

TABLE 3: STUDY OUTCOMES
Outcomes
Patient demographics
Antropometrics: Height &
Weight, goniometry
Vignos Scale

Data Collected by
Site Clinical Coordinator
Physical Therapist

10MWT

Physical Therapist

Supine to Stand

Physical Therapist

4 Stair Climb

Physical Therapist

Quantitative Muscle Strength
from CQMS (QMT)

Physical Therapist

Physical Therapist

Method of data collection
Data entered into EDC
Paper source & Data entry
into EDC
Paper source & Data entry
into EDC
Paper source & Data entry
into EDC
Paper source & Data entry
into EDC
Paper source & Data entry
into EDC
Direct transfer from CQMS
system to EDC

Description of study outcomes
Patient demographics and medical history was collected in the study. Data used for this
analysis included race, ethnicity, age, height, weight, and steroid usage history.
G ONIOMETRY
Clinically significant contractures are defined as a reduction in ROM by 20 degrees. Joint
ROM measurements followed the protocol used by Brooke and colleagues238 using standard
goniometry as previously reported by Johnson113. Measurements for contractures included
elbow and knee extension, wrist extension, and ankle dorsiflexion. For patients who are unable
to transfer to the exam table, ROM was be measured while participant was seated in the
wheelchair.
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Passive Range of Motion Testing Procedures: All measured bilaterally
1.) Ankle Dorsiflexion
•

Measured in supine with the knee extended as much as
possible.
• The goniometer center is placed over the lateral
malleolus, arms are aligned with lateral midline of the
fibula using head of fibula for reference, and parallel
to the lateral aspect of the fifth metatarsal.
• Full Normal Range= 20 degrees
2.) Knee Extension
•
•
•

Measured in supine with hip in neutral, ankle relaxed.
Goniometer center is placed lateral to knee joint (lateral epicondyle of femur), arms are
aligned with midline of the femur using greater trochanter for reference, and lateral
midline of the fibula using lateral malleolus for reference.
Full Normal Range= 0 degrees

V IGNOS LOWER EXTREMITY SCALE
The functional classification used by CINRG utilizes a scale modified from and the lower
extremity scales used by Vignos et al.1 This scale was administered and rated by the physical
therapists who were evaluating the participants in the study. The scale includes eight levels to
describe the ability to get hands over head, hand to mouth to ability use his hands (Figure 5).
Timed Function Testing
Timed motor performance (e.g. 10MWT, time to climb 4 stairs and time to stand from the
floor) tests followed the protocol reported by CINRG group. If the patient was unable to
perform the test, the test was skipped and re-introduced at the next visit.
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Timed Test Procedures
10MWT
The participant stood at the beginning of a measured 10-meter length of hallway or walkway.
He was then asked to traverse the 10 meters as quickly and safely as possible. This test was
performed without shoes.
Equipment: Stopwatch, 12-meter hallway.
Instructions: The participant stood with his hands by his side. On the word “go” he was asked
to go as fast as he can past the 10-meter mark. The evaluator stopped the time when the first
foot passes the 10-meter mark. (cold start, flying finish)
4 Stair Climb
The participant stood at the foot and center of the stairs, without holding the rails. He was
asked to climb the 4 stairs and stop on the top platform without turning around. When he
reached the top, the participant stood still and returned his hands to his sides to end the test.
Use of the railing was allowed if preferred by the participant. The participant was not to skip
any stair.
Equipment: Stopwatch, Standard 4 steps with railing
Instructions: The participant was asked to start on “go” and climbed the stairs as quickly and
safely as possible. The evaluator stopped the timer when the participant was standing with
both feet on the top stairs, feet within shoulder width apart and hands by his side. (start in
soldier position; end in soldier position)
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Supine to Stand
The participant laid on the floor with arms at sides if able. If unable participant was able to sit
in a chair with his hands folded in his lap or across his chest. The chair height allowed the
participant’s hips and knees to be at 90 degree angles with feet resting on floor. The
participant was told to stand up as quickly as he can while maintaining arms crossed across
chest. After standing the participant returned his arms to his sides to end the test.
If the participant was unable to perform the sit to stand without the use of his upper body, then
the participant was able to sue the arm of the chair or push up from the floor. This is noted in
the study worksheet.
Equipment: Stopwatch, Low pile carpet or linoleum floor
Instructions: The participant was positioned with arms by his side and legs hip width apart or
as close as possible due to IT band tightness. The participant was asked to get up from the
floor as quickly and safe as he possible on the word “go”. The evaluator stopped the timer
when the participant was standing with both feet within shoulder width apart and hands by his
side.
Timed function test data (10MWT, Supine to stand, 4 stair climb) was collected in seconds using
a standard stopwatch. Statistical analysis utilized the data expressed as speed (Table 4) with
imputed zeros for those who cannot perform the test due to disease progression.
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TABLE 4: VELOCITY CALCULATIONS FOR 3 TIMED TESTS

10MWT

Speed Calculation

Example

10/seconds to run/walk
Units = meters
walked/second

If it takes a boy 5 seconds to perform test
10MWT=5 sec
Velocity=10/5=2m/sec

Supine to Stand

1/seconds to stand
Units = rise/second

If it takes a boy 3 seconds to stand up, his
velocity is being able to accomplish a third
or 0.33 of the task per second
If it takes him 5 seconds, his velocity is 0.2
of the task per second, or he accomplished
one fifth of the task in one second.

4 Stair Climb

The entire task of climbing the 4 stairs
combined is used, rather than a per step
unit, which would not reflect a meaningful
entity

1/time to climb
Units = 4 stairs/second

If it takes a boy 9 seconds to climb 4 stairs
1/9=.11/sec
Q UANTITATIVE M USCLE T ESTING
QMT of the knee and elbow flexors and extensors was performed by the methods
described by Escolar (Table 5).67 QMT has been shown to be reliable for these muscle groups,
with an intraclass correlation coefficient (ICC) greater than 0.90.
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TABLE 5: QUANTITATIVE MUSCLE TESTING PROCEDURES
Muscle
Group
Knee
Extensors

Patient Position

Limb Position

Sitting with back
support, facing away
from the wall

-Hip and knee flexed at
90 degrees-Towel roll
under tested knee

Stabilization
Seat belt;
Chest strap if
needed;

Limb Strap
Position
Proximal to
malleoli

Examiner
stabilizing proximal
thigh
Knee
Flexors

Sitting with back
support, facing
toward the wall

-Hip and knee flexed at
90 degrees-Towel roll
under tested knee

Seat belt;
Chest strap if
needed;

Proximal to
malleoli

Examiner
stabilizing distal
thigh
CQMS SYSTEM
Data from the CQMS system is a stand-alone software and hardware package which
facilitates collection of data from quantitative muscle testing (QMT), manual muscle testing
(MMT), timed function tests (TFTs), functional evaluation (FEs) and pulmonary function testing
(PFTs). Design and validation of this system has been previously reported.67 This system leads
the physical therapists at each study site step by step through a standardized set of assessments
and at the conclusion of the battery of tests resulting data is backed up locally to compact disc
and then transmitted via a remote connection to a central directory on one of the OmniComm
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TrialMaster’s servers. All data is copied by the OmniComm TrialMaster system to a secure
backup server at another site several times per day.
The study manager, data monitor, biostatisticians and DSMB had access to the entire
study dataset throughout the entire study. This was for monitoring of specific site data, for
performing quality control, for periodic data analysis, or for study-wide monitoring. These
individuals only had read-only access to the study data via the TrialMaster CQMS web interface.
Where the content or integrity of a specific data point was in question, site specific individuals
were responsible for answering the query for comment/revision. Any data revised or altered in
any way was captured by the system’s audit trail mechanism.
Pursuant to 21 CFR Part 11, the data management system for the CQMS and the
OmniComm Trialmaster system complied with all federal regulations regarding electronic
signatures, audit trails, and date and time stamps; collection, inspection and review of data,
retrieval of data, and reconstruction of the study; physical and logical security; system
documentation, validation and change control; software version control, system failure
contingency plans, backup and recovery of electronic records; personnel qualifications, training
and documentation.
DATA ANALYSES
GENERAL CONSIDERATIONS FOR CLINICAL DATA USED IN THIS STUDY
Clinical outcomes in this study included knee strength, 10MWT, Supine to stand, 4stair
climb measures. Most of the measures are continuous and quantitative. Descriptive analyses
were grouped based on the distribution of data.
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For continuous measures, histograms, box and whisker plots and Q-Q plots were used to
assess normality, need for transformation of data and to identify outliers. Normality was assessed
using a combination of the Shapiro-Wilk normality test and visual inspection of histograms.
Measurements were summarized for each visit and the 12-month change from baseline. The
operational definition for a 12-month change is considered 305-426 days). If distribution was
approximately normal, mean and standard deviation were reported. For non-normal distributions,
median, minimum-maximum and interquartile ranges were reported. For categorical data,
frequencies and percentages were reported.
To get a true representation of the cohort, patients who lost the ability to perform the time
function tests during the study were included in analyses by imputation of velocity. If the
participant lost the ability to perform a task since the previous visit due to progression of disease,
a velocity value of 0 was imputed for the first visit where they could not accomplish the task.
The participant was then excluded for that test in subsequent visits.
Due to differences in definition for ambulation and steroid use, we operationally defined
these descriptions in this study. Patients were considered non-ambulatory if they reported full
time wheelchair use at the time of the visit or if they reported the age at which a wheelchair was
used full-time. All other patients were categorized as ambulatory which encompass both
household and community ambulators. Steroid use was defined for each visit and based on
patient report of steroid use during time of the visit. Descriptive analysis also summarized the
total duration of steroid use up to each visit.
THE RELATIONSHIP BETWEEN STRENGTH, ROM, AND FUNCTION (FOR OBJECTIVES A-C)
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Objectives A-C include describing the relationship between knee extensor strength, range
of motion, and 3 timed function tests. Descriptive statistics to describe the data, then the ability
of knee strength and ankle ROM to predict walking, climbing, or standing ability was analyzed
using mixed effects linear models. All statistical tests were performed with STATA V15
(College Station, TX) and a p-value of ≤0.05 was considered statistically significant.
Descriptive summary statistics such as age, gender, ambulatory status data were
presented as mean and standard deviation and median, minimum, and maximum values.
Summary statistics of both absolute values of knee extensor and ankle dorsiflexion and 12-month
changes in knee extensor and ankle dorsiflexion were calculated and reported with several
different categorizations. Summaries were calculated for each of the above-named outcomes
stratified by 1-year age groups and either glucocorticoid use or ambulatory status. In these
summaries, all available data points were used for each participant, therefore many participants
contribute more than one observation per stratified group. The number of data points and the
number of unique participants were reported for each stratified group. For summaries of 12month changes, the glucocorticoid and ambulation status at the beginning of the 12-month period
were used for purposes of stratification. For this analysis participants were divided into the 5
stages based on age. For example, if a participant was 4.5 years old at the start of the 12-month
period, they were included in the 0 to 4.9 year age group even though they were older than 4.9
years at the end of the interval.
To assess the relationship between knee extensor strength, knee ROM, and ankle
dorsiflexion ROM and functional ability, mixed effects linear models were used. The goal was
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to assess how useful these strength and ROM assessments are at predicting functional abilities
(i.e. the ability to walk, climb stairs, or stand from the floor). In each model the functional ability
was considered the dependent variable and strength, or range of motion was the independent
predictor. Age and glucocorticoid use (yes/no dichotomous variable describing use at the time of
the visit) were included as covariates and each model included a random coefficient for
participant. This model allowed assessment of the relationship between the predictor and the
dependent variable while allowing for multiple related assessments per participant. Each model
provided an estimate of the amount of change in functional outcome that can be attributed to the
predictor while accounting for covariates and repeated measurements taken on the same
participants. In addition, the model provided a significance test for each predictor. Several
mixed effect models were performed. These included models where 1) walking velocity,
climbing velocity or standing velocity was the dependent variable and the absolute value of knee
extensor strength, knee ROM, or ankle ROM was the independent predictor and 2) the 12-month
change in walking velocity, climbing velocity or standing velocity was the dependent variable
and the 12-month change in knee extensor strength, knee ROM, or ankle ROM was the
independent predictor.
Lastly, to assess the combined effect of knee extension strength and ankle ROM on
functional ability, three additional mixed effects linear regression models were performed. In
these models, both knee extension strength and ankle ROM were included as independent
predictors and walking velocity, climbing velocity or standing velocity was the dependent
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variable along. Models again included covariates for age and glucocorticoid use and a random
coefficient for participant.
This cohort represents a wide range of ages and the full spectrum of functional abilities.
DMD progression rate is variable at different stages of the disease. This analysis described range
of motion and strength based on the 5 stages of function, as previously described. The
breakdown provided a more granular understanding of differences in ROM and strength within
the different stages. It also allowed evaluation of the relationship between knee strength/ROM in
the lower limbs and functional ability at different stages of the disease.
MINIMALLY CLINICALLY IMPORTANCE DIFFERENCE ANALYSIS
An anchor-based method was used to define the MCID in the ability to walk, stand, or
climb stairs. Clinical meaningfulness of walking, standing, and climbing were assessed by
anchoring them to changes in the Vignos functional scales. Descriptive statistics were used to
summarize participants’ age, current usage of steroids and 12 month change of clinical endpoints
grouped by Vignos decline status decline status.
Logistical regression models, adjusted for age, were used to test 12 month changes in
timed function tests associated with a 12 month decline in the Vignos score. Participant IDs were
clustered to account for multiple occurrences of more than one 12 month interval measurements.
This clustered sandwich estimator specified that the standard errors allowed for intragroup
correlation, and also affected the variance-covariance matrix of the estimators. The model was
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as follows: Vignos decline status= 12 month function change of each time function outcome +
age, stratified for ambulation with clustering on subjects.
In order to identify the anchor based MCID, the timed function tests were associated with
a Vignos decline of p values less than 0.05. Candidate MCID values were developed with use of
receiver operating characteristic curve analysis following the ROC sensitivity to change method
by Stratford et al.239 To obtain anchor based MCID, a new binary variable for each of the 3 timed
function tests was developed, namely, the new binary variable of 1 or 0 based on whether the 12
month change of time function tests were < the cutoff score. The optimal cutoff point was
estimated by the point with maximum likelihood ratio obtained by dividing sensitivity (true
positive rate) by 1 minus specificity (false positive rate).239 A logistic regression model was then
fit to the new binary variable.
INSTRUMENTS, MEASURES AND DESIGN THREATS
With increases in the numbers of experimental therapies and clinical trials in DMD, it is
important to define reliable and sensitive endpoints that fulfill FDA requirements for relevance
to quality of life. The key to a successful clinical trial is the utilization of reliable outcome
measures.31 The primary outcome measure should have demonstrated relevance to patient quality
of life, but also be sensitive and reliable.31, 240 Both sensitivity and reliability ensure that clinical
trials can be appropriately powered with a reasonable number of patients, and thus at a
reasonable cost. Reliability is particularly important for multi-site clinical trials, with
demonstrated inter-class correlation coefficients sufficient for conducting the trials with a
reasonable number of patients.
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Two more recent methods for assessing muscle strength use mechanical (analogue or
digital) measures of force generated by the DMD patient; hand-held myometry (HHM), and the
CINRG Quantitative Measurement System (CQMS). Quantitative muscle testing (QMT), where
isometric strength is monitored by patient maximal voluntary contraction against a force
transducer, has become a common method in neuromuscular research to best assess isometric
strength in adults. To increase reliability and sensitivity in children (e.g. DMD), a QMT system
interfaced with audiovisual feedback was developed by the CINRG group and called CQMS
(CINRG quantitative measurement system). In essence, the audiovisual feedback turns the
strength measurement process into a ‘video game’, leading to increased compliance and effort
(reliability) in DMD children.67, 241 A reliability study produced by CINRG found the CQMS to
have high sensitivity and reliability for large multi-center trials in children with Duchenne
Muscular Dystrophy.241
The MD-CARE Act passed in 2001 brought to the forefront a large initiative to allocate
federal funding that encompasses these goals.31 One of the key issues from the FDA focused on
clinical trial endpoints that have proof of principle data to incorporate a functional
component.31This has led to the need to find surrogate outcomes. In order to reach this point, we
must identify a sensitive and reliable measure of strength related to functional outcomes, such as
walking, that may correlate to quality of life. If a primary clinical endpoint shows poor reliability
and/or sensitivity, then the required statistical powering of the study requires many more
patients. In fact, even relatively small decreases in reliability and sensitivity can significantly
increase the number of DMD patients needed for the trial, to the point of becoming exceedingly
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expensive and problematic for adequate recruitment. A second important issue, particularly for
pharmaceutical companies, is acceptance of a trial endpoint by the FDA as relevant to the
‘quality of life’. While it may seem intuitive that improved muscle strength should improve the
quality of life of DMD patients, the FDA argues that this cannot be assumed to be true unless
clearly demonstrated. For example, statistically significant (but small) increases in strength
could be associated with worsening of contractures or other side effects that would not lead to
improved quality of life.
Timed function tests are increasingly used as clinical trial endpoints in neuromuscular
disease, as these are readily accepted by FDA as relevant to quality of life. Timed function tests
have been found to correlate with quantitative muscle strength in different stages of the disease
process in DMD; a small reduction in muscle forces showed a large decrease in functional
ability.242 Due to some subjectivity in timed function test secondary to confounding variables
such as fatigue and motivation, many clinical trials also employ a quantitative measure to assess
functional status. Any confounding variable serves to reduce the sensitivity and reliability of the
test, decreasing statistical power, and increasing the number of patients to detect change. This
can lead to ‘failure’ of a trial, even though there is other evidence of strength improvement and
improvements in quality of life.
In order to show the relationship between body systems, function and quality of life, the
International Classification of Functioning, Disability and Health (ICFDH) was developed by the
WHO. It aimed to progress DMD research by providing a common framework and language for
clinicians and scientists across all domains toward an anticipated clinical endpoint. This model
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standardized the definition of body functions and measures to make comparable observations and
develop appropriate design tools throughout each phase of clinical development31. The ICFDH
improved the communication between basic scientists and clinical researchers to parallel
endpoints relevant to proposed anticipated outcomes of a clinical trial. A common tool to assess
strength measures that correlate with “life-altering” outcomes would be important in order to
find surrogate measures. Without these measures, it would be difficult to find intrinsic meaning
in strength data and measures of functional outcomes. A valid and sensitive strength measure
will propel correlations in surrogate measures to improve the ability to predict clinically
meaningful outcomes such as ambulation and quality of life. These factors from the ICF create a
good framework to base the correlation of health parameters to endpoint assessment in
translational research.
Direct measurements of strength, either of isolated muscle groups or combined scores of
multiple muscles, have long been used for clinical trials in DMD and other neuromuscular
disorders. The most heavily utilized approach has been ‘manual muscle testing’ (MMT), where
a trained evaluator manually assesses the strength of a patient, typically on a 1-10 scale. MMT
was used extensively by the CIDD group, and shown to be sensitive and reliable with highly
trained evaluators.32, 98 Clearly, MMT is entirely based upon subjective assessments of clinical
evaluators, and the experience of the evaluator becomes a strong potential confounder,
decreasing sensitivity and reliability. To date, there has been data to support quantitative muscle
testing as a sensitive and reliable measure to assess muscle weakness.67, 240-246 However, there
fails to be a study that investigates and directly compares reliability and sensitivity of the two
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most widely used isometric quantitative muscle testing devices: hand held dynamometry and
quantitative muscle testing. Both these strength measures have been demonstrated to be more
reliable and sensitive than manual muscle testing.67, 240-246
Strength and functional assessments performed in this retrospective analysis included
strength assessments using the CINRG Quantitative Measurement System (CQMS). CQMS
requires a strain gauge to determine maximal isometric contraction. The advantage of a strain
gauge system such as the ability for it to assess a range of very strong to very weak muscles. This
is important as DMD is a slow progressing disease, and it is essential to have a sensitive method
to measure strength progression throughout the course of the disease.
The CQMS incorporates a standard sequence of assessments, audiovisual feedback, and
real time data checks designed to improve effort-dependent strength measures and test
performance. This system has the capability of recording pulmonary function tests, timed
function tests, functional tests, range of motion, and manual muscle testing in a standardized
fashion. For the purposes of this study, we will only use the strength measures function.
Variability appears to be less in QMT versus manual muscle test measures.247 A study by
Mayhew et al (2007)241 showed a high level of agreement between “expert” evaluators and
newly trained evaluators (Table 6).
TABLE 6: STRENGTH RELIABILTY
Measurement

Expert Evaluators
ICC
Confidence Interval
(2 SD)
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Novice Evaluators
ICC
Confidence Interval (2
SD)

Total Manual Muscle
Test Scores
Total Quantitative
Muscle Test Score

0.83

0.32-.94

0.61

0.3-0.80

0.97

0.93-0.98

0.96

.092-0.98

Comparison of expert versus novice evaluator differences in muscle testing showed a
much larger confidence interval with manual muscle testing compared to quantitative muscle
testing for both experts and novice evaluators, indicating much more variability in the manual
muscle test data. CQMS measures appear to be more consistent with a higher ICC and much
narrower confidence intervals, indicating less variability in the data for CQMS testing.241 Other
assessments used in this study include functional measures of timed functional tests (10-meter
walk test, supine to stand and stairs) as well as an ordinal scale of lower extremity function, the
Vignos Lower Extremity Scale.
Anthropometric measurements relevant in the analysis included standing height measured
by a stadiometer with standard standing posture requirements, weight measured in kg, and joint
ROM measured by a standard goniometer following procedures by Norkin.248 Lower extremity
ROM measurements used in this retrospective analysis included knee extension and ankle
dorsiflexion. It is important to note the quality and reliability of joint range measurement relies
largely on the physical therapist’s knowledge of anatomy and physiology for proper alignment of
the axis of the goniometer to the fulcrum of the joint and positioning. Additional factors affecting
measurement error include the force applied to the end range, end range feel, test position, and
instrumental differences.249-251 We recognize that there are other methods to measure ROM but
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chose the standard goniometer as most of these methods have an equitable reliability to
goniometry with intraclass correlations between 0.85 and 0.99.249
STRENGTHS AND WEAKNESSES OF STUDY DESIGN
STRENGTHS:
Understanding the natural history of DMD is essential to building clinical understanding
for care management, and a requirement to understand the impact of interventions. This natural
history study has furthered the development of psychometric soundness of strength and timed
function tests used in DMD. With this large dataset, methodology, feasibility, reliability,
sensitivity and magnitude of these clinical outcome measurements have been developed and
validated. The advantage of this study design allowed for all individuals with DMD regardless of
functional status to learn and participate in a clinical trial. This broad inclusion criteria is expected
for natural history studies as it better generalizes a representation of patients around the world.
This study design consisted of a rigorous methodology in training and administration of
clinical evaluations, which is not always the case for earlier natural history studies. Patients
enrolled in the study came into a separate clinic visit from their normal clinic visit which allowed
for focused time with the evaluators. Additionally, CINRG has an established infrastructure to
provide training and consistency with administration of physical therapy evaluations to ensure
standardization and reduce drift of knowledge. All data used in this analysis was evaluated by a
licensed physical therapist who met the minimal annual training criteria. This is crucial in
reducing variability in data. A physical therapy training plan was developed to ensure
consistency of the evaluations throughout the length of the study which consisted of initial face
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to face training, reliability assessment, and annual refreshers throughout the study. Other
methods to ensure quality data included a rigorous data cleaning plan that included range checks
for data entry into the electronic database, and clinical sensibility checks performed throughout
the entirety of the study. Despite the heterogeneity in the disease progression of DMD, the
CINRG training and data management plan helped reduce the usual variability in clinical
outcomes that can be a problem in natural history studies.
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Weaknesses:
The greatest weakness in the study may also be considered a strength of the study.
Despite the advantage of the inclusive nature of this study, it lends to increased heterogeneity in
the data for a complex disease with well-known variability in disease progression rates.
Additionally, patients in this study were recruited from different parts of the world. Because this
study recruited internationally, the different SOC around the world contributed to added
variability in patient presentation. It is well documented that the 2 primary factors impacting
changes in clinical presentation for boys with DMD are the use of steroids and management of
contractures. Steroid use varies in regard to dosing, frequency, and type; while stretching and
brace management have even greater variability. All of these traits make it difficult to
determine clinical meaningfulness in these measures with a small sample size. Here, given the
inclusive nature of the study, we were able to recruit a large cohort for a rare disease giving us
larger numbers than typically available in smaller studies.
ETHICAL CONSIDERATIONS AND REVIEW
All individuals participating in the CINRG DMD natural history study consented to
participation in the study using standard forms provided by CINRG and approved by each local
institutions Institutional Review Board (IRB) or Ethics Committee (EC). All 26 sites submitted
to their local IRB and received approval prior to initiation of any study related activities.
Informed consent/assent was documented for each patient in any study. The date and
time of the consent/assent was made prior to the initiation of any study-related tests or
procedures, including diagnostics that might be required to confirm a patient’s study eligibility.
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Consent included dialogue with the investigator, parents and patient. All informed consent forms
were written at the 8th grade reading level without technical language, and including an
explanation of study procedures, risks and benefits of performing the assessments, and
participation in a natural history study. For international locations, all consents/assents were
translated to the primary language of the patient and family. Translation of the consent/assent
document was certified in writing by a certified translator. All patients were provided with a
copy of the informed consent/assent.
CONFIDENTIALITY AND HEALTH INFORMATION PORTABILITY AND ACCOUNTABILITY ACT
(HIPAA)
Confidentiality was maintained throughout the study. A unique code rather than a name
was used to identify test results and study data. No personally identifiable information was
released beyond the Study Coordinating Center and data center without prior written consent of
the patients. All records were kept in a HIPAA-approved secure facility. Medical history,
questionnaire response data, and information collected from medical records is all considered
personal health information (PHI) as per guidelines set forth by HIPAA. Data was entered by
site staff into a large, registry-style secure database that was under the control of the CINRG
Coordinating Center and was stored in a de-identified coded manner using unique study ID
numbers. Any information collected following cessation of a patients being in the study was
destroyed, but information collected during their participation remained as the part of the overall
study data set.
The case report form collection electronic data capture systems were HIPAA-compliant,
and the computers were password protected and accessible only to study personnel. All CINRG
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Coordinating center personnel who had access to the database performed the necessary Human
Subject Protection training.
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Summary
This is a retrospective review of data collected prospectively from a longitudinal natural
history study for boys with DMD ages 2-28 years in 28 centers throughout the world. The
objective of the study was to better understand the disease progression for boys with DMD in the
era of corticosteroid therapies. This analysis included 440 individuals who completed at least one
year of data collection between the years of 2006-2009 and 2012-2016. Inclusion and exclusion
criteria were set to ensure that all patients enrolled in the study had DMD and not the milder
phenotype, BMD. The protocol was approved by each institutions’ ethical review board with
appropriate consents/assents prior to enrollment into the study.
Clinical outcome measures included multi-organ assessments, but this analysis focused
on musculoskeletal related outcomes of ankle ROM, knee strength and timed function tests that
are associated with loss of ambulation. Individuals were assessed at 3, 6, 9 and 12 months during
the first year followed by 18 and 24 months and annually thereafter. Standardization of study
procedures was ensured through rigorous hands on training, reliability testing and quality control
review of data throughout the trial.
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Data analysis in this study aims to better understand variables that contribute to loss of
function in individuals with DMD who are still ambulatory. Correlation of strength, range of
motion and function will provide better understanding of factors that may predict loss of
ambulation. Anchor-based methods to provide MCID values were calculated to help better
understand the clinical meaningfulness of these changes. Conclusions from this study will
contribute to proactive care management and to improve design of clinical trials for a rare
disease where limited recruitment numbers are a limiting factor to the success of trials, thus
making the determination of the appropriate patient and endpoint selection crucial in the success
or failure of a study.

99

CHAPTER 4: MANUSCRIPT 1: CHARACTERIZATION OF CONTRACTURE
DEVELOPMENT AND EFFECTS ON FUNCTION IN DUCHENNE MUSCULAR
DYSTROPHY: IN THE ERA OF GLUCOCORTICOIDS
Author: Tina Duong1,2
Contributions: Conceived and implemented study design; Analyzed data. Wrote first draft of
manuscript
Co-author: Jennifer Canbek3
Contributions: Provided feedback on statistical analysis. Provided edits on early manuscript drafts
Coauthor: Erik Henricson5
Contributions: Conceived study design. Provided input on early statistical advice.
Coauthor: Marisa Birkmeier7
Contributions: Implemented study design. Provided early manuscript draft edits. Provided field
expertise.
Coauthor: Catherine Siener4
Contributions: Implemented study design. Provided early manuscript draft edits. Provided field
expertise
Coauthor: Alicia Fernandez-Fernandez3
Contributions: Provided feedback on statistical analysis. Provided edits on early manuscript drafts
Coauthor: Heather Gordish-Dressman6
Contributions: Conceived study design. Provided field expertise and performed statistical analysis.
Provided manuscript draft edits.
Journal: Journal of Neuromuscular Disease
Status of Manuscript:
_x Prepared for submission to a peer-reviewed journal
_Officially submitted to a peer-review journal
_Accepted by a peer-reviewed journal
_Published in a peer-reviewed journal
Date of anticipated submission Feb 15, 2020

100

101

Abstract
Duchenne Muscular Dystrophy (DMD) is a neuromuscular disorder that presents in
childhood characterized by slowly progressive proximal weakness and lower extremity
contractures that limit ambulatory ability.1,2 Contractures develop in the ankles, knees, and hips
due to muscle imbalances, fibrotic changes, loss of strength, and static positioning.2,5 Currently,
standards of care (SOC) guidelines emphasize the importance of maintaining good
musculoskeletal alignment through stretching, bracing, and glucocorticoid (GC) therapy to
maintain strength and function.
A collection of timed function tests (TFT) supine to stand, 10 meter walk test (10MWT),
and timed stair climbing, have been used to monitor disease progression and are predictive of loss
of ambulation in these patients.4 A better understanding of how other assessments used in clinic,
such as strength and range of motion (ROM), predict loss of these functions is important in more
individualized rehabilitation management.
The objectives of this analysis are to understand the progression of contractures for
individuals with DMD and to investigate the relationship between progressive lower limb
contractures, strength, and TFTs.
Keywords:
Duchenne muscular dystrophy, gait, contracture, strength
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Introduction:
Duchenne muscular dystrophy (DMD) is a progressive genetic neuromuscular disease
affecting 1 in every 7250 males from ages 5-24 years.2, 3 This X -linked developmental disorder
causes progressive muscle weakness, usually leading to death by early adulthood. Individuals with
DMD have a mutation in the dystrophin gene which leads to musculoskeletal impairments
including progressive muscle weakness, imbalances, and contracture development which
eventually result in loss of ambulation.4 Discovery of the dystrophin gene over 30 years ago has
led to improved diagnostic and treatment capabilities in people with DMD. Improved physical
therapy (PT) management strategies and therapeutic interventions result in a longer lifespan for
individuals with DMD and contribute to the increased variability in rates of disease progression.
Phenotypical progression varies in DMD but occurs in a predictable, sequential manner that
includes the loss of functional abilities (e.g. ability to rise from the floor, climb stairs, walk, and
self-feed) with eventual premature death due to cardiorespiratory insufficiency.5, 6, 8, 13, 14, 21, 22, 40
Physical therapy goals focus on addressing muscle imbalances around joints to maintain
optimal biomechanics for movement and energy conservation. Proximal hip flexor, hip extensor,
and knee extensor muscle weakness is seen initially. Contractures typically first develop distally
in the ankles followed by the hip flexors, iliotibial bands, and forearm/finger musculature.8
Significant contractures are rare in children younger than 9 and tend to develop more aggressively
as they lose the ability to stand or walk.8 This supports the theory that contracture development is
multifactorial with physiological and environmental components. Due to the high rate of fibrosis
in DMD, muscles with poor anti-gravity strength positioned in a shortened position will develop
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contractures.5,

8-11

Progressive muscle weakness and the development of contractures change

musculoskeletal alignment and affect muscle force demands, which translates functionally in
decreased gait speed and eventual loss of ambulation.15-18
Currently, standards of care guidelines for DMD emphasize an anticipatory care approach by
maintaining

appropriate

musculoskeletal

management

through

physical

therapy

and

Glucocorticosteroids (GC) to maintain strength and function.42, 43 GCs are frequently used for
individuals with DMD and have beneficial effects on TFTs as reported by multiple studies.6, 36, 40,
61, 151, 152, 252, 253

However, few studies have studied the possible effect of GCs on the onset and

progression of ankle contractures nor their impact on TFTs in DMD.
There is a consensus on a collection of clinical assessments, including TFTs, that should be
used both in DMD-focused multidisciplinary clinics and clinical trials due to their ability to track
disease progression and prognostic capabilities.254 Since gait speed has been shown to be a good
predictor of loss of ambulation,35 it is important to understand the implications of contractures on
gait speed. Contracture management and GC use are the few published interventions that have
changed the natural history of the disease;40 3, 5, 6, 8, 13, 14, 32, 34-36, 60-62 therefore, understanding the
effects of shortening in specific muscle groups can be clinically meaningful. Muscle imbalances
and associated ankle contractures change the biomechanics of gait and may contribute to loss of
ambulation.12-14 For example, a minimum of neutral ankle range of motion (0 degrees) allows for
better vertical alignment of the body’s center of gravity in standing and assists in accomplishing
foot clearance through the swing phase of ambulation.16, 18
The 10MWT has been typically used to assess gait speed in DMD and is an important predictor
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in loss of ambulation.35 Understanding the effects of impairment-based changes on the
biomechanics of gait and the resultant loss of functional activities will influence proactive clinical
decision-making. For clinicians, understanding how TFTs, strength assessments, and ankle range
of motion are associated with the loss of ambulation will help make proactive care management
decisions, including timing of equipment or orthotic recommendations. In clinical trials, this
information is beneficial for trial design to determine the appropriate efficacy endpoint, study
population, and timeline.
Objective
Currently, there is minimal evidence to help physical therapists provide quality anticipatory
plan of care for contracture management. The objective of this study is 1. Understand contracture
onset and progression in boys with DMD 2. Explore the impact of contributing factors such as
ankle ROM, knee strength, age, and GC use on losses of functional abilities such as the ability to
walk, transition off the floor, and climb stairs.
Method:
Data was collected through the CINRG Duchenne Natural history study, a consortium of
22 sites in over 9 countries. Design and methodology was based on previously published study
design and methodology.29, 255 All clinical sites had institutional or ethics review board approvals
prior to data collection. Informed consent/assent was obtained for each participant and/or caregiver
prior to study procedures. This analysis included 440 individuals who had at least one range of
motion assessment during the study collected between 2006 and 2016. Assessments were
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performed at baseline and months 3, 6, 9, 12, 18, 24 (ambulatory) or months 6, 12, 18, 24 (nonambulatory) followed by annual visits after year 3. Historical and current GC use was obtained
throughout the study.
Standardized methods and training were observed throughout the trial for all physical
therapy assessments to ensure consistency of measurements. Data extracted for analysis included
TFTs, specifically supine to stand, climb 4 stairs, and 10 Meter walk/run (10MWT); fixed
quantitative strength measures (QMT) of knee extension/flexion; and passive range of motion
(PROM) measurements which included knee extension and ankle dorsiflexion. TFT variables were
assessed in seconds but expressed as speeds for analysis and reporting. PROM was measured in
degrees, and QMT was measured in pounds (lb.) of force.
Equipment and training: Timed tests were measured using a standard stopwatch and
Sammons Preston 4 stairs with bilateral handrails. Instructions included standard start and stop
positions. All timed tests started with hands by side and feet within base of support. End position
for supine to stand and stairs were the same as the start position. The 10MWT end position included
when the patient’s first leg passed the 10-meter line (cold start, flying finish). Quantitative muscle
testing was assessed using the CINRG Quantitative Measurement System (CQMS) developed and
validated as a reliable measure for strength in boys with DMD.67, 241 Passive range of motion
(ROM) measurements were assessed using a standard goniometer. Knee and ankle ROM were
measured in supine (Figure 1). Ankle ROM was measured in the best obtainable subtalar neutral
position. Passive measurement into dorsiflexion was measured with positive values indicating
more dorsiflexion, while negative values indicated loss of dorsiflexion past neutral (0 degrees).
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Methodology for all assessments followed a detailed manual and worksheets with standard test
positions throughout the trial.
All physical therapists participating in this study followed CINRG standards for
certification including central training and support provided by the Central Evaluations Manager
(CEM). Certification encompassed initial hands-on training and reliability testing, annual webinar
to review data quality and reduce drift in administration of items, and bi-annual face to face handson meetings.
Statistical analysis was performed using STATA V15 (College Station, TX). Clinical
outcomes in this study included range of motion assessments, knee strength, 10MWT, supine to
stand, and 4-stair climb measures which were continuous and quantitative variables. Descriptive
analyses were grouped based on the distribution of data.
For continuous measures, histograms, box and whisker plots and Q-Q plots were used to
assess normality and the need for transformation of data. Normality was assessed using a
combination of the Shapiro-Wilk normality test and visual inspection of histograms.
Measurements were summarized for each visit including the 12-month change from the baseline
assessment. The operational definition for a 12-month change is considered 305-426 days. If the
outcome’s distribution was approximately normal, mean and standard deviation were reported. For
non-normal distributions, median, minimum-maximum, and interquartile ranges were reported.
For categorical data, frequencies and percentages were reported.
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TFTs were collected using a standard stopwatch. Statistical analysis utilized the data
expressed as speed: (1) 10MWT = m/s, (2) supine to stand = rise/second, and (3) 4 stair climb = 4
stairs/second. To get a true representation of the cohort, patients who lost the ability to perform
the TFTs during the study were included in analyses by unit imputation of zero for the respective
test. If the participant lost the ability to perform a task since the previous visit due to progression
of disease, a value of 0 was entered for the first visit where they could not accomplish the task.
The participant was then excluded for that test in subsequent visits. The three TFTs were treated
independently.
Due to differences in definition for ambulation and steroid use, we operationally defined
these descriptions in this study. Patients were considered non-ambulatory if they reported full-time
wheelchair use at the time of the visit, or if they reported the age at which a wheelchair was used
full-time. All other patients were categorized as ambulatory, encompassing both household and
community ambulators. GC use was defined for each visit and based on patient report of steroid
use at time of the visit. Descriptive analysis also summarized the total duration of GC use up to
each visit.
Summary statistics of both absolute values of knee extensor and ankle dorsiflexion and 12month changes in knee extensor and ankle dorsiflexion were calculated and reported with several
different categorizations. Summaries were calculated for each of the above-named outcomes,
stratified by 1-year age groups and either glucocorticoid use or ambulatory status. In these
observational summaries, all available data points were used for each participant; therefore many
participants contribute more than one observation per stratified group. The number of data points
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and the number of unique participants is reported for each stratified group. For summaries of 12month changes, the GC and ambulation status at the beginning of the 12-month period were used
for purposes of stratification. For this analysis participants were divided into the 5 stages based
on age. For example, if a participant was 4.5 years old at the start of the 12-month period, they
were included in the 0 to 4.9 year age group, even though they were older than 4.9 years at the end
of the interval.
To assess the change in knee and ankle ROM over time and the effect of GC use we
performed mixed models with repeated measures. Each model included the ROM outcome as the
dependent variable, age (representing time) as the independent variable, and a random coefficient
for each participant. Models were run separately for those currently using GCs and those who were
not. A third model assessed an interaction between age and GC use.
To assess the relationship between knee extensor strength, knee PROM, and ankle
dorsiflexion PROM and functional ability, we again used mixed models with repeated measures.
The goal was to assess how useful these strength and PROM assessments are at predicting
functional abilities (i.e. the ability to walk, climb stairs, or stand from the floor). In each model,
the functional ability was considered the dependent variable, and strength or PROM was the
independent predictor. Age and GC use (yes/no dichotomous variable describing use at the time
of the visit) were included as covariates. Each model included a random coefficient for each
participant. Models included only data on participants while ambulatory. The models allowed us
to assess the relationship between the predictor and the dependent variable while allowing for
multiple related assessments per participant. Each model provided an estimate of the amount of
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change in functional outcome that can be attributed to the predictor, while accounting for
covariates and repeated measurements taken on the same participants. In addition, the model
provided a significance test for each predictor. Several models were built. These included models
where 1) walking speed, climbing speed or standing speed was defined as the dependent variable
and the absolute value of knee extensor strength, knee PROM, or ankle PROM was the
independent predictor and 2) the 12-month change in walking speed, climbing speed or standing
speed was the dependent variable and the 12-month change in knee extensor strength, knee PROM,
or ankle PROM was the independent predictor.
Lastly, to assess the combined effect of knee extension strength and ankle PROM on
functional ability, three additional mixed effects linear regression models were performed.
Variables used were based on known clinical observations and published research significant
predictors of functional decline in DMD.5, 29, 40 In these models, both knee extension strength and
ankle PROM were included as independent predictors and walking speed, climbing speed or
standing speed was the dependent variable. Models again included covariates for age and
glucocorticoid use and a random coefficient for each participant.
Results:
A cohort of 440 participants and 1321 observations were used for analysis. Patient
demographics are in table 1. GC use was stratified based on duration on drug with 18.7% with <6
months or naïve; 4.3% <1 year; 58.0% 1< 10 years; and 19.3% between 10-25 years of GC use.
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GC’s appear to have an effect on ankle ROM in boys beginning at age 9, those taking GC’s have
a greater observed ankle ROM than those not taking GC’s.(Figure 2 and Table 2). Ankle and knee
contractures were observed to increase after ambulation was lost based on boys typical age at loss
of ambulation. Progression of contractures over a 12-month period for both knee and ankle PROM
showed very minimal changes for either GC or naïve groups. On average, for knee PROM, there
was a -1 degree change over a year, whereas ankle PROM had a mean change of 3.6 degrees over
one year with the greatest observed change being -5 degrees (Figure 3). Ankle PROM are very
similar in early ages however shows a distinct difference in rate of decline based on GC use. When
estimating the change in ankle and knee ROM over time (table 4), those not on GCs exhibited a
greater decline than those who were on GCs. Ankle ROM declined an average of -3.28 degrees
per year in those not taking steroids, but only -1.86 degrees per year in those taking steroids. Figure
4 shows this sharper decline clearly.
Assessing longitudinal data over the life span indicated that QMT, PROM, age, and GC
use are all key variables that are significantly related to a decrease in functional ability.
Observation of ambulatory and non-ambulatory ankle PROM median values show ankle PROM
is more negative in the non-ambulatory versus ambulatory participants at all ages. For those who
are ambulatory, the median value for any participant who was still ambulatory was -10 degrees
(Table 3). This study found that once accounting for age and GC status, TFT values were
significantly predicted by knee strength and ankle PROM. The results of these mixed effect linear
models for the 10MWT are shown in table 5. This demonstrates that an increase in knee strength
or PROM predicted a statistically significant increase in walking speed. When evaluating the
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combined predictive effect of knee extensor strength and knee PROM (Table 6), knee extensor
strength predicted the greatest change in speed. A single pound increase in knee extensor strength
predicted a 0.042 m/s increase in walking speed whereas a single degree of improvement in PROM
predicted only a 0.009 m/s increase in walking speed. In all cases, speed significantly decreased
with age and those who were not currently on GCs. We did assess changes in ROM over a 12month period, the typical length of an interventional clinical trial, although due to small changes
in PROM over a 12-month period of this analysis, there were no significant relationships with
change in PROM with TFT performance nor was there a significant effect of GC use in this short
time frame. However, 12-month changes in both knee extensor and flexor strength showed a
significant relationship with declines in TFT performance (data not shown).
Discussion:
This study describes the onset and progression of contractures in the largest longitudinal
natural history study in boys with DMD. With the alteration in the disease course from the standard
use of GC for disease management and the recent developments in drug therapies, there has been
great interest in understanding the downstream effects of contractures on strength and function
across the spectrum of disease progression. Improvements in standards of care including
management of primary and secondary effects of DMD with physical therapy, GC use, respiratory
care, coronary care, and contracture management have led to longer ambulation status and
lifespans.53 Once an individual becomes non-ambulatory, there is increased economic burden on
the family and increased risk for secondary issues such as the development of scoliosis,
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osteoporosis, obesity, disuse atrophy, increased rate of contracture development, and psychosocial
issues related to the loss of function.
The economic impact of longer survival is associated with much higher medical costs,
especially in the later stages of the disease. Medical costs are nearly 6x higher for those who are
non-ambulatory compared to those who are ambulatory,
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thus making it critical to better

understand the reasons that contribute to loss of ambulation. Understanding the variability in
contractures and strength allow for more individualized anticipatory care and justification for
rehabilitation-related interventions that have been associated with reducing the effects of
contractures, such as night orthosis256, serial casting187, 198, 199, frequency of stretching7, 190, and
timing of ordering equipment.
Our study findings validated previous studies on the prevalence of ankle contractures in
ambulatory DMD boys.5, 257, 258 These study results are consistent with other published studies
showing that ankle dorsiflexion contractures are associated with decreased function. Kiefer et al258
found that increased ankle PROM contractures resulted in lower Northstar Ambulatory
Assessment scores, a 17-item functional assessment of gross motor skills such as walking, standing
and jumping validated in boys with DMD. Akkurt et al259 assessed timed function tests including
the 6MWT and found a moderate significant correlation of ankle PROM on TFTs. Mendell et al32
initially found positive effects on strength and function and no changes on contractures; however
based on our results, we believe 6 months may not be long enough to understand impacts on
contracture. However, none of these studies evaluated progression of contractures and its possible
impact on disease progression. Our study results did not show a significant relationship with a 12113

month change of PROM and TFT. This may be due to the very small ROM changes over a 12month period and suggests that 12 months may be too short of a timeframe to see changes in
contracture progression even though strength does show significant declines during this period.
Our results showed, for the first time, possible impact of GC use on progression of ankle
contractures. Ankle ROM was similar among boys in the early ages of the disease but those who
were GC naïve appeared to have a faster rate of ankle contractures indicating that GC treatment
may affect the rate of contracture development which may directly impact care management
especially for those who are not using GC as part of their SOC.
Previously published studies have associated time required to complete the 3 timed tests
(supine to stand, 4-stair climb, and 10MWT) with loss of function in DMD.40 Gait speed is
determined by the power generated within the gait cycle in both the stance and swing phases. This
power is dependent on both pelvic girdle muscles and the gastroc-soleus complex affecting both
phases of the gait cycle. There is significant decrease in power generation and absorption in both
of these phases for individuals with DMD due to the early weakness of the hip flexors and extensor
muscles and tightness of the plantarflexors. This does not allow for peak hip extensor force during
terminal stance phase. There is also decreased hip flexor propulsion for pre-swing and reduced
push off during terminal swing due to plantarflexion contractures.18, 125 In the Cohen et al260 study
of 15 boys with DMD and 336 healthy controls found that boys with DMD had a reduction in their
walking rate beginning at ages 4-6. In a study looking at EMG activity during gait, Ropars et al120
found that rectus femoris and hamstrings were active throughout most of the gait cycle in boys
with DMD, indicating the need for stability with muscle weakness.
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Gait studies have shown that ankle contractures contribute to decreased gait speed at the
initial stance phase.128 In boys with DMD, it serves a different purpose because it acts as a
biomechanical advantage by providing an extension moment during the stance phase of gait to
oppose knee flexion moments, allowing the center of gravity line to fall in front of the knee.123, 128
However, with disease progression, the excessive ankle plantarflexion contractures and increased
hip and knee weakness lead to added instability during stance17, 18 and result in a tipping point
where the biomechanical advantage does not override the muscle weakness. Houx et al261 found
that -10 degrees of dorsiflexion was the threshold at which gait kinematics changed for typically
developing children. For children with muscle weakness, these gait changes could be detrimental
in maintaining ambulation. The results of our study validate the kinematic findings from Houx et
al261 indicating that that -10 degrees appears to be a critical value of dorsiflexion loss that puts
boys at greater risk of losing ambulation.
One of the primary limitations in this study is that it is a natural history study. Therefore,
factors such as GC and contracture management were not controlled. Interventions that may
impact contractures such as stretching and orthotics were not assessed and therefore not accounted
for in the analysis, which may have an impact on progression. Additionally, based on Heberer’s125
study showing decreases in peak hip extensor moments in boys with DMD, it would have been
informative to understand the contribution of hip extensors in gait speed. However, this study did
not measure pelvic girdle muscles which may be a significant factor in gait speed, as knee
flexion/extension may act more as a method of stability rather than power generation. Future
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studies should investigate the contribution of typically weakened muscle groups, such as hip and
pelvic musculature, on gait in individuals with DMD.
Conclusion
In conclusion, there is a great degree of variability in contracture development in boys with
DMD, especially in the GC era. Our study found that ankle and knee PROM was better for those
on GC and effected long-term progression rates. However, the minimal progression of contractures
in our study when limited to 12-month may be indicative that the 1-year period may be too short
to assess changes in contractures.
Significant factors affecting functional speed include knee extension, PROM, GC use, and
age, with knee extensor strength having more of an impact than ankle ROM. Loss of ankle
dorsiflexion of >10 degrees affects the kinematics of gait261 and is detrimental. This combined
with muscle weakness may put boys with DMD at risk for losing ambulation. Results from this
long-term follow up of DMD boys show that knee strength along with management of contractures
are important to maintain the ability to walk, climb stairs, and stand. These results contribute to
improved understanding of the progression of strength and ROM on the DMD disease trajectory
thus an important piece of the puzzle that is needed to understand impacts of SOC for clinical
management and how it may be incorporated in clinical trials design.
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Figures and Tables
MANUSCRIPT 1: FIGURE 1: PROM PROCEDURES
1.) Ankle Dorsiflexion
•

Measured in supine with the knee extended as much as
possible.
• The goniometer center is placed over the lateral
malleolus, arms are aligned with lateral midline of the
fibula using head of fibula for reference, and parallel
to the lateral aspect of the fifth metatarsal.
• Full Normal Range= 20 degrees
2.) Knee Extension
•
•
•

Measured in supine with hip in neutral, ankle relaxed.
Goniometer center is placed lateral to knee joint (lateral epicondyle of femur), arms are
aligned with midline of the femur using greater trochanter for reference, and lateral
midline of the fibula using lateral malleolus for reference.
Full Normal Range= 0 degrees

MANUSCRIPT 1 TABLE 1: QMT PROCEDURES
Muscle Group

Patient Position

Limb Position

Stabilization

Limb Strap
Position

Knee Extensors

Sitting with back
support, facing
away from the
wall

•

Hip and knee
flexed at 90
degrees
Towel roll under
tested knee

•
•

Proximal to

Sitting with back
support, facing
toward the wall

•

Hip and knee
flexed at 90
degrees
Towel roll under
tested knee

•
•

Knee Flexors

•

•
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•

•

Seat belt,
chest strap if
needed
Examiner
stabilizing
proximal thigh
Seat belt,
Chest strap if
needed
Examiner
stabilizing
distal thigh

malleoli

Proximal to
malleoli

MANUSCRIPT 1 TABLE 2: STUDY DEMOGRAPHICS

Characteristic

N (%)

Median (min, max)

Age (years) – At baseline visit

440

8.9 (2.1, 28.0)

Age (years) – At last study visit

440

14.6 (4.5, 33.9)

Ambulatory status – At last baseline
Ambulatory

292 (66.4%)

Non-ambulatory

148 (33.6%)

Ambulatory status – At last study visit
Ambulatory

192 (43.6%)

Non-ambulatory

248 (56.4%)

MANUSCRIPT 1: FIGURE 2 ROM STRATIFID BY GC USE

Knee ROM by Age (years)

0

Ankle ROM

Not on GC

Not on GC

On GC

Abbreviations: GC=Glucocorticoid, ROM=Range of Motion
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On GC

17+ yrs

13-16 yrs

9-12 yrs

5-8 yrs

0-4 yrs

17+ yrs

13-16 yrs

9-12 yrs

5-8 yrs

0-4 yrs

-150

-100

-50

-50
-100

Knee ROM

0

50

50

Ankle ROM by Age (years)

MANUSCRIPT 1 TABLE 3: ANKLE DORSIFLEXION MEASUREMENTS
Degrees of Ankle Dorsiflexion
(Ambulatory)

Degrees of Ankle Dorsiflexion (Nonambulatory)

Age
N
N
Median
N
N
Median
interval
Min Max
Min Max
(Obs) (Ind.) (Degrees)
(Obs) (Ind.) (Degrees)
(years)
<4.9

100

51

10

-10

30

0

5.0 to
8.9

685

216

5

-50

25

3

2

-7

-30

-3

9.0 to
12.9

365

155

0

-52

20

42

35

-20

-80

10

13.0 to
16.9

137

67

0

-70

15

61

39

-25

-75

10

17+

29

15

-10

-35

5

87

46

-30

-80

0

MANUSCRIPT 1: FIGURE 3 12-MONTH CHANGES OF ANKLE ROM STRATIFIED
BY AMBULATORY STATUS

Degrees
-20
20
0

Ambulatory

Non-ambulatory
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17+ yrs

13-16 yrs

9-12 yrs

5-8 yrs

0-4 yrs

-40

12 month change in Ankle ROM

40

12-month change in Ankle ROM by Age (years)

MANUSCRIPT 1 TABLE 4: CHANGE IN ROM OVER TIME
ROM
assessment

GC use status

Not on GC
Knee ROM

N (obs)

Coefficient (pN (indiv.) value)
321
145
1270

On GC

285

Not on GC
Ankle ROM

281
126
1228

On GC

277

-2.78 (<0.001)
Yes (p<0.001)
-2.05 (<0.001)

-3.28 (<0.001)
Yes (p<0.001)
-1.86 (<0.001)

4: CHANGE IN ANKLE ROM OVER THE STUDY

-100

-50

Ankle ROM

0

50

MANUSCRIPT 1: FIGURE
STRATIFIED BY GC USE

0

10

20
Age

Presence of significant
interaction

30

40

Blue: participants taking GCs at the time of the study visit
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Black: participants not taking GCs at the time of the study visit
MANUSCRIPT 1 TABLE 5: STRENGTH AND ROM AS INDEPENDENT PREDICTORS
OF 10M RUN/WALK

Predictor of 10MWT
Knee flexor QMT
Knee extensor QMT

N (obs)
N (indiv.)
1555
263
1570
265

Predictor

Age

Steroid use

Coefficient (p-value)

Coefficient (p-value)

Coefficient (p-value)

0.031 (p<0.001)

-0.131 (p<0.001)

0.222 (p<0.001)

0.039 (p<0.001)

-0.104 (p<0.001)

0.195 (p<0.001)

Knee ROM

1305
283

0.014 (p<0.001)

-0.108 (p<0.001)

0.340 (p<0.001)

Ankle ROM

1300
284

0.009 (p<0.001)

-0.101 (p<0.001)

0.348 (p<0.001)

MANUSCRIPT 1 TABLE 6: THE COMBINED EFFECT OF KNEE STRENGTH AND
ROM ON TFT

Knee extensor Ankle ROM
(lb)
(degrees)

Age (years)

Steroid use

Coefficient (p- Coefficient (pvalue)
value)

Coefficient
(p-value)

Coefficient (pvalue)

Outcome

N (obs)
N (indiv.)

Run/walk
velocity

1073
265

0.042
(p<0.001)

0.009 (p<0.001)

-0.086
(p<0.001)

0.193 (p<0.001)

Climb
velocity

1033
265

0.012
(p<0.001)

0.002 (p<0.001)

-0.017
(p<0.001)

0.039 (p<0.001)

Stand
velocity

954
264

0.007
(p<0.001)

0.002 (p<0.001)

-0.020
(p<0.001)

0.036 (p<0.001)
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Abstract:
Duchenne muscular Dystrophy (DMD) is a rare x-linked recessive genetic disorder affecting 1 in
every 5000-10000.53, 262 This disease leads to a variable but progressive sequential pattern of
muscle weakness that eventual leads to loss of important functional milestones such as the ability
to walk. With promising drugs in development to ameliorate the effects of muscle weakness, these
treatments must be associated clinically meaningful functional change. The objective of this
analysis is to determine both distribution (minimal detectable change (MDC)) and anchor-based
(minimal important clinical difference (MCID)) of 12-month change values in standardized time
function tests (TFT) used to monitor disease progression in DMD.
Method: This is a multi-center prospective natural history study with the Cooperative International
Neuromuscular Research Group (CINRG). This study calculated MID and MCID values for 3
commonly used timed function tests typically used to monitor disease progression; supine to stand
(STS), 10-meter walk(10MWT), 4 stair climb(4SC). MID used standard error of measurement
(SEM) while MCID measurements used the Vignos scale as an anchor to determine clinical change
in functional status.
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Results: All 3 TFT were significantly important clinical endpoints to detect MDC and MCID
changes. MDC and MCID 12 month changes were significant in 10MWT (-0.138, .-0.212), Supine
to Stand -0.026, -0.023) and 4 stair climb(-0.034, -.035) with an effect size greater or close to 0.2.
Conclusion: The 3 TFTs are clinically meaningful endpoints used to establish change in DMD.
MDC values were higher than MCID values indicating that an anchor-based approach using
Vignos as an anchor for functional loss of lower extremity abilities is appropriate to assess change
in boys with DMD.
Keywords:
Duchenne muscular dystrophy, MCID, time function tests
Introduction:
The most common form of pediatric onset muscular dystrophy is Duchenne muscular
dystrophy (DMD), caused by a genetic mutation in the dystrophin gene that leads to progressive
muscle weakness and loss of ambulation. DMD affects 1 in every 5000-10000.2,

53, 262

The

discovery of this gene over 30 years ago led to improved diagnostic capabilities for DMD.4
Standards of care guidelines for DMD emphasize appropriate musculoskeletal management
through physical therapy and corticosteroid therapy to maintain strength and function. These
interventions have resulted in a longer lifespan yet increased variability in disease progression.
DMD progression occurs in a predictable sequential manner with loss of the ability to get off the
floor, climb stairs, bring hands to mouth, and early morbidity due to cardiorespiratory
insufficiency.5, 6, 8, 13, 14, 21, 22
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Predictive factors of disease progression are associated with the loss of major functional
milestones such as walking ability. With corticosteroids, the timeline when young boys lose
ambulation has shifted by 1-2 years however is still inevitable between the ages 9-15.37 Walking
speed in boys with DMD is directly correlated with prolongation of ambulation, indicating that
individuals who walk faster maintain ambulation longer.

8

There have been numerous studies

linking ambulation to improved quality of life and prevention of the development of scoliosis, and
joint contractures/deformities.7,

8, 13

Once an individual becomes non-ambulatory, secondary

issues such as development of scoliosis, osteoporosis, obesity, disuse atrophy, increased rate of
contracture development and psychosocial issues impact the perception of disease progression.
The psychological effects of loss of a function are similar to the fears and anxiety that is associated
with loss felt at the time of diagnosis for boys and families with DMD.38
In 2006, at a National Institute on Disability and Rehabilitation Research (NIDRR) meeting to
discuss challenges in muscle disease, the FDA specified that clinical trials conducted in support of
new drug approvals or revised indications for already approved drugs must incorporate a primary
endpoint that objectively measures a clinically meaningful “life-changing” milestone that has a
significant impact on a patient’s perceived overall health and well-being.31 Historically, the Vignos
scale, an 8 point ordinal scale, has been used to describe lower extremity function in boys with
DMD with each level indicating a change in function including significant milestones such as loss
of ability to rise from the floor and ambulation.1, 40 In a study by McDonald et al39, the authors
noted high correlation with the PODCI transfers/basic mobility score, a patient reported outcome
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measure, with the Vignos scale and 3 timed function tests including supine to stand, 10 meter
run/walk and 4 stair climb.
To determine clinically meaningful difference in clinical assessment measures, there are
anchor-based (MCID) and distribution-based (MDC) methods which are distinctly different
approaches to provide meaningful estimates of change for outcome measures. They are
increasingly employed in disease-based treatment development research.229-232 In the anchorbased approach, the meaningfulness of the change in a study measurement is determined based on
the ability of a change score to predict the occurrence of a clinically meaningful milestone in the
natural history of the disease.232, 233 MCID is the minimal amount of change to a clinical outcome
that may make a difference in clinical care or quality of life to a patient.63, 234
MDC has been described as true change that is not attributed to error or variability.
Distribution-based methods depend on statistical approaches founded on psychometric soundness
of a clinical outcome, without reference to a clinical or patient perspective of change. The timed
function tests analyzed in this study have been reported to have sound psychometric properties of
reliability and validity, as well as good predictive qualities.40, 67, 241 These properties give assurance
that changes in these clinical endpoints are less likely to be due to measurement error. MDC is a
statistical approach not anchored to clinical significance.63 Statistical change does not necessarily
translate to clinical benefits. MDC values use direct approaches that compare different groups,
whereas MCID methods, use an anchor-based approach to establish a meaningful change over
time.71
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Anchor-based approaches use clinical or patient interpretation to understand the magnitude
of change and is typically compared with other clinical measures.71 On a guidance document about
patient-reported outcomes, the FDA attempted to provide guidance on interpretation and
implications of MCID measures.235 However, due to lack of consensus, MCID was defined as the
smallest difference in outcomes that may be proxies of perceived importance to patients.235 With
little guidance, clinical trials continue to report MDC measures of change, which may under or
overestimate the clinically important differences or significance of results. This becomes a
problem as payers tend to require clinical outcomes used in trials as a minimal criterion for
payment.
Many studies report velocity measures as predictors of loss of function in DMD.5, 29, 30, 35,
40, 58, 70, 228, 263, 264

However, there needs to be better understanding of the clinical impact of different

change trajectories of timed function tests (TFTs) and its impact on loss of functional milestones.
MCID estimates that are based on rate of change can provide a threshold for meaningful change
that is important to the patient. MCID measures are not only important to patients46, but they can
provide clinicians with a critical value that corresponds to a measurable change helping determine
clinical goals and disease monitoring to improve anticipatory care management. It is also
increasingly important to payers, since they often define approval or payment for therapies based
on published MCID values. It is essential that researchers accurately report MCID estimates which
are specific to a particular patient population to improve the access to care in specific populations.
Additionally, MCID values can help determine appropriate sample sizes when designing clinical
trials for better interpretation of clinical outcomes and relevance to disease progression.48 The
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objective of this paper is to determine and compare MDC and MCID values of 3 validated and
commonly used TFTs (10MWT, STS, 4SC) on disease progression and its impact on function
for individuals with DMD.
Methods:
Data was collected as part of the CINRG Duchenne Natural history study, a consortium of 22
sites in over 9 countries. Prior to data collection, all sites had had institutional or ethics review
board approvals and informed consent/assent was obtained prior to study procedures. The study
population included 391 individuals with DMD with at least 7 years of follow up data. Data was
collected between 2006-2016. Assessments were performed at baseline and months 3, 6, 9, 12, 18,
24 (ambulatory) or months 6, 12, 18, 24 (non-ambulatory) followed by annual visits after year 3.
Corticosteroid use was also captured at each visit.
Standardized methods and training were observed throughout the trial for all physical
therapy assessments to ensure consistency of measurements based on previously published design
and methodology.29, 30, 241, 255. Data extracted for analysis included TFTs, specifically 10MWT,
STS, 4STS and Vignos scale scores (Fig1). The Vignos Lower extremity scale is an ordinal scale
used to describe lower extremity functional ability in boys with DMD with higher values
representing lower function. Any changes in the Vignos scale would reflect functional loss. TFT
variables were assessed in seconds and reported as speed. Example of conversions are below
10MWT speed = 10/seconds to complete the test, resulting in an assessment value in m/s
•

10MWT test=5 seconds
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•

Velocity=5sec=10/sec=2m/s

4STS speed= 4/seconds to complete the test, resulting in a speed assessment per step
•

4STS= 2 seconds

•

Velocity= ½=0.5 of the task per second

STS speed= 1/seconds to complete the test resulting in an assessment in rises/s.
•

STS=2 seconds

•

Velocity= ½=0.5 of the task per rise
For 12-month changes, we determined the number of participants with at least one 12-

month interval of assessments where 12 months was defined as two visits >=304.2 days (47.3
weeks) and <=425.8 days (64.7 weeks) apart. We excluded intervals that overlapped by more than
91.3 days (13 weeks). The final data set for statistical analysis contained 1518 records from 391
individuals. The Vignos scale is organized with higher scores indicating less function while lower
scores indicate higher function, thus a decline in score indicates an improvement in function.
Vignos was used as a clinical anchor defined as a binary variable: 0=no decline (score remained
the same or decreased by 1 or more points over the 12-month interval) or 1=decline (score
increased by 1 or more points over the 12-month interval). Independent variables included the 3
TFTs with covariates of age and corticosteroid status (user/non-user) at the start of each 12-month
interval.
All statistical tests were performed using STATA V14 (College Station, TX). Statistical
tests were conducted using a two-tailed test at an alpha level at 0.05. Descriptive statistics were
used to summarize participants’ age, current usage of steroids and 12-month change of clinical
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endpoints grouped by Vignos decline status. T tests or chi square tests were used to test for
significant differences in these variables between Vignos decline status. We also used the
sensitivity- and specificity- based approach to compare change of outcome scores from TFTs to
the decline status of 12-month changes in the Vignos scale.
Logistic regression models, adjusted for age, were used to assess the 12-month changes
in timed function tests associated with a 12 month decline in the Vignos score. Participant IDs
were clustered to account for multiple occurrences of more than one 12-month assessment
interval. The model specified Vignos decline status as the dependent variable, 12-month change
in each time function outcome as the dependent predictor, age and steroid status at baseline as
covariates, and was clustered on individual participants. Models were stratified by ambulation
status.
In order to define the anchor based MCID as a candidate, the timed function tests must
have been associated with a Vignos decline at a p value less than 0.05. Candidate MCID values
were then developed with use of receiver operating characteristic curve (ROC) analysis
following the ROC sensitivity to change method by Stratford et al.239 To obtain anchor based
MCIDs, a new binary variable for each of the 3 timed function tests were developed, namely, the
new binary variable of 1 or 0 based on whether the 12 month change of time function tests were
< the cutoff score. The optimal cutoff point was estimated by the maximum point reached from
the ROC analysis; the largest value defined by dividing sensitivity (true positive rate) by 1 minus
specificity (false positive rate).239 A logistic regression model was then fit to the new binary
variable.
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In order to calculate the observed distribution-based MDC values for our cohort, we used
the effect size approach and observed baseline and 12-month change values. The MDC was
estimated as the 12-month change in time function score divided by the standard deviation of
each time function outcome at baseline.
Results:
The dataset consisted of 391 participants with at least one 12-month interval for a total of 1518
observations. Of those, 826 observations were used for this analysis based on ambulatory status.
Patients were on steroids during 70.8% of their 12-month intervals (82.7% for baseline
ambulatory patients). Consistent with published clinical data on loss of ambulation, the average
age for ambulatory individuals was 9.1 years (Table 1). Assessment of age and corticosteroid
use as potential covariates showed only age to be significantly associated with Vignos scores;
therefore, only age at baseline was used as a covariate unignorably in the anchor-based model
fitting.
For Vignos model fitting, all three TFTs were associated with Vignos status with an
adjusted p value < 0.05 and had acceptable AUC values of > 0.7 within the ROC analysis. AUC
is often used as a statistical model fitting indicator where values of 0.7 ~ 0.8 are considered
acceptable, that of 0.8 ~ 0.9 to be fairly good, and that of 0.9 ~ 1.0 to be excellent.265 Table 3
shows the distribution based and anchor based MDC and MCID values. MDC estimates were
calculated from the stand deviation of baseline endpoints. MCID measures show significant pvalues of <0.05 in the prediction model fitting for all 3 TFTs.
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Effect size is a standardized measure of change from baseline over a certain time interval
divided by the standard deviation (SD) of the baseline score. The effect size value represents the
number of SD by which the scores have changed from baseline. By convention, an effect size of
0.2 is considered small, 0.5 moderate and 0.8 large.266 The MCIDs anchored to Vignos scores for
2 of the 3 timed tests were slightly larger or near equitable indicating that MDC is not as
meaningful a change and there is a need for an anchor based approach for clinical
meaningfulness (Table 2); this included 10MWT (MCID=-0.212m/s, MDC=-0.138m/s) and
STS (MCID =-0.023 task/sec MDC=-0.026). MCID values show that a small change in velocity
measures resulted in a change in Vignos status by at least one level. As DMD is a progressive
disease, all individuals showed a decline. For example, in the 10MWT, a -0.212m/s decline in
gait speed resulted in a clinically meaningful unit change on 1 in the Vignos scale.
Discussion:
These TFTs are well established and frequently used in trials and the clinic because of their
ease of administration.254 Having a measure that is easy to administer and reliable is important to
be used as efficacy endpoints in clinical trials. As noted in more recent approved trials in Spinal
Muscular Atrophy, clinical endpoints used in trials are becoming insurance requirements for
authorization for access to the treatment.267, 268
Most published studies in DMD which have determined clinically meaningful differences
have used both MCID and MDC values. MDC measures are a good estimate of the psychometric
properties of an instrument but MCID values must be used to link the change to a clinically
meaningful functional change in disease milestones. Estimates of MCID of functional speed
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measures anchored to a validated scale like the Vignos 8-point ordinal scale in DMD
categorizing lower extremity function44 aligns with the National Heart Blood Lung Institute’s
(NHBLI) recommendations on estimating MCID values for diseases with a wide heterogeneity
and also shown to be better applicability in clinical interpretation and efficacy trials.45-47
Additionally, the importance of being able to anchor the rate of change in TFTs to the Vignos
scale is clinically important as a change in level tends to trigger a change in care needs. For
example, the inability to get off of the floor or ambulate may require need for equipment,
changes in school individual education plans or home modifications which all require at least 6-9
months to make these modifications. Therefore, having an MCID score that may be used to
better predict loss of functional level in the Vignos could be very useful in an anticipatory care
approach. Early planning would help clinicians ease the pain of such losses in function for
families by providing proper planning and appropriate supports in place with better anticipation
of these losses.
Despite the paucity of little research45, 48, 49, 57-59 using natural history studies to determine
MCID scores, this study looked at DMD natural history to determine MCID scores associated
with change scores over 12 months that is associated with loss of function, instead of treatment
effectiveness. Determining MCID values in the context of disease deterioration is important to
understand the true impact of future therapeutic interventions and management compared to
basing it on a single time point. SOC has changed the health outcome for boys with DMD
despite lack of approved treatments. In this natural history study, calculating MCID based on rate
of annual progression takes into account more than one timepoint that may impact prediction of
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functional loss thus providing a better understanding of the timeframe and impacts of SOC. In a
study of Chronic Obstructive Pulmonary Disease, a retrospective study assessed MCID values to
determine 6MWT MCID values that may be good predictors of mortality or hospitalization, and
found that observational studies were more robust to answer these questions because of the lack
of confounding treatment interventions.45
Understanding the etiology, symptomology, and natural history of degenerative diseases is
essential in determining MCID values that are relevant to the prediction of loss of functional
milestones and its impact on the health-related quality of life measures.45. There is also a need to
understand the MCID changes for clinical outcomes used throughout the entire spectrum of
DMD’s disease progression, future analysis will look at strength and pulmonary function
measurers that also encompass individuals who are non-ambulatory.
Conclusion
Applying MCID values to commonly used clinical assessments helps appropriately power
clinical trials as well as contribute to clinical decision making. MCID values in this study is
based on rate of disease progression on an untreated population. Therefore, in a clinical trial, if a
treatment improves the rate of change for these TFTs then there may be a clinically meaningful
change that is linked to a significant functional milestone loss. MCID values may be
instrumental in demonstrating a meaningful objective change that affect clinical management
and determination of treatment efficacy. This may be used as a guide for clinicians to adjust
treatment plans, anticipate and justify equipment needs.
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Results from this study is the first to report minimally important changes in timed function
tests that are anchored to crucial loss of functional milestones on the Vignos scale. These tests
are frequently used in the clinic and clinical trials and are well validated to be sensitive to disease
progression. With variations in disease progression, it is important to understand the impact of
the rate of change in these TFT measures for proper anticipatory care planning and clinical trials
design.
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MANUSCRIPT 2: FIG 1: VIGNOS LOWER EXTREMITY SCALE
1. Walks and climbs stairs without assistance
2. Walks and climbs stairs with aid of railing

3. Walks and climbs stairs slowly with aid of railing (over 12 seconds for 4 standard stairs)

4. Walks unassisted and rises from chair but cannot climb stairs.
5. Walks unassisted but cannot rise from chair or climb stairs.
6. Walks only with assistance.

7. Participant is dependent on wheelchair for all mobility.
8. Participant is in bed at all times.
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MANUSCRIPT 2 TABLE 1: STUDY DEMOGRAPHICS
Vignos

Variable

Level

Steroid
Status

Non- Steroid
User
Steroid
User N(%)

Age

N = 1518

N=
826

444 (29.2)

143
(17.3)

1074 (70.8)

683
(82.7)

No Decline

Decline

N=520

N=256

103

24

(81.1)

(18.9)

417

232
(35.75)

(64.25)

N

1416

776

Mean

13.07

9.117

8.502

10.598

Std Err

0.158

0.117

0.14

0.19
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520

256

Adjusted P
value
0.307

<.001

MANUSCRIPT 2 TABLE 2 DESCRIPTIVE STATISTICS OF 12 MONTH CHANGES OF
CLINICAL ENDPOINTS BY VIGNOS STATUS

12 month rate of change
(m/sec) 10 meters

N

1394

Mean

-0.085

Std Err
N
12 rate of change (rise/sec) of
Mean
standing from supine

12 month rate of change
(step/sec) of 4 steps

754

508

246

-0.159

-0.05

-0.398

0.008

0.015

0.016

0.023

1337

697

479

<.001

218

-0.010

-0.020

-0.012

-0.039

Std Err

0.001

0.003

0.003

0.004

N

1360

720

Mean

-0.011

Std Err

0.0018

490

230

-0.022

-0.005

-0.06

0.004

0.005

0.004

<.001

<.001

MANUSCRIPT 2 TABLE 3: MDC AND MCID VALUES FOR
TFTS ANCHORED WITH VIGNOS
Timed Function Test 12 month speed Change

MDC

10 MWT

-0.138 m/sec

-0.212*m/sec *#

-0.026 rise/sec

-0.023rise/sec *#

-.0.034 steps/sec

-0.035steps/sec*#

Supine to Stand
4 Stair Climb

Note: * indicates p value <0.05; # indicates AUC >=0.7
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CHAPTER 6: SUMMARY
DMD is an x-linked genetic neuromuscular disorders that impair the production of
dystrophin resulting in a fragile muscle membrane triggering a cascade of downstream problems
with inflammation, necrosis, abnormal regeneration/degeneration of normal muscle function.2, 53,
262

It is a lethal progressive disease primarily affecting boys showing early loss of motor function

and premature mortality from cardiopulmonary complications. Since the discovery of this gene
over 30 years ago4, there has enriched understanding of the pathophysiology and phenotypical
manifestations of DMD and its multi-organ impacts for boys affected by this disease. Increasing
scientific understanding of DMD has led to an explosion of drug developments in the last decade
that addresses the many causes and consequences from the lack of dystrophin.
As a physical therapist working in a multi-disciplinary clinic and research team, it is clear
that this disease severely impacts quality of life and function for boys with DMD with significant
impact on the entire family unit. Families spend a disproportionate amount of time in the medical
arena while juggling to keep a balanced “normal” household. With contracture management
being one of the few treatments recommended for musculoskeletal health in DMD, families have
struggled with time to perform the daily stretches and guilt associated with the ineveitable
development of contractures in their boys. This project was born out of desire to relieve the
DMD community and families of the blame associated with contracture development by better
understanding how contractures may develop and impact disease progression. To start this
journey, I investigated the relationship of strength on function and the use of GC on the most
prevalent contractures in boys with DMD, ankle plantarflexors. To understand how this may
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impact changes that result in important modifications to clinical care and decision making, I
determined MCID values for commonly used timed function tests that have been associated with
loss of meaningful functional milestones such as walking. Changes in function for boys with
DMD require an anticipatory care approach. Being able to predict care needs is important in
adjusting stretching or bracing management for contractures, make recommendations for
equipment, home/school modifications, changes to school Individual Education Plans and
psychosocially prepare families for a loss of a functional milestone.
In this retrospective analysis of the largest international natural history study in DMD of
440 boys, I first wanted to understand if there were differences in the development and
progression of ankle ROM in GC naïve and those on GC by calculating change of ROM over a
12 month period using mixed models with repeated measures approach. The results indicated
that those on GC had slower progression of ankle contractures by -3.28 degrees per year
compared to GC naïve (-1.86). To better understand the contributions of strength, ankle ROM
and GC use on these TFTs, mixed effects linear regression model models were used to better
understand the contributions of each of these variables to the speed at which patients with DMD
can complete each of the 3 TFTs. We found that all 3 of these variables statistically significantly
contributed to TFTs but knee extensor strength and GC were greater contributors and the
combination of all 3 of these variables may be better predictors of loss of ambulation than
strength or GC alone. In order to understand the clinical implications of TFT as predictors of
disease progression, we calculated MCID and MDC scores based on an annual rate of change of
the TFT anchored to the Vignos LE scale used to describe changes in lower limb function in
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boys with DMD. MCID values showed that a small change in how quickly boys were able to
perform the TFTs resulted in a change in Vignos status by at least one level. As a clinician, a
decline in one level of the Vignos will trigger changes in my plan of care. In the 10MWT, a 0.212m/s decline in gait speed over one year period resulted in a clinically meaningful change by
1 level on the Vignos scale.
Most published studies have established that TFT are good indicators of disease status
and used as predictors for loss of ambulation.5, 29, 30, 35, 40, 58, 70, 228, 263, 264,37 However, most of
these values are based on a single timepoint and does not take into consideration different rates
of progression. Boys with DMD have a sequential progression of motor weakness but highly
variable in disease progression especially in the GC era. Therefore, having MCID values
established on an annual rate of decline provides more accurate prediction of loss in function.
In this past year, over 30 drugs are in the DMD pipeline ranging from restoration of
dystrophin, reducing inflammation to providing stability to muscle fibers. Most of the primary or
secondary clinical endpoints used in these studies are TFTs. As indicated by the FDA in a recent
meeting on DMD platform trials designs, Drs Janet Woodcock and Billy Dunn emphasized the
need to better understand clinical outcomes in the context of disease progression and an evolving
standard of care to improve disease outcomes. Clinical endpoints must be standardized, easy to
administer, have good inter and intra rater reliability, show convergent and construct validity as
well as good clinically meaningfulness. In the pre-GC era, TFTs have been used as an efficacy
measure in the early studies and its standardization has been consistently administered in
neuromuscular clinics, natural history and industry sponsored studies.254 Having a wealth of data
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from TFTs allows for the DMD community to aggregate this data for better understanding of the
DMD disease profile. We know that TFTs are good predictors of function but there was still a
gap in linking it to something meaningful. The results of this study tries to address this by
determining MCID values associated with these tests and lower limb function.
In rare diseases, recruitment of patients become difficult with more therapeutic
opportunities. Therefore, we need to have better understanding of commonly used clinical
outcomes and its impact on the mechanism of disease allowing scientists to more confidently
extrapolate data from smaller studied groups into understanding possible effects in a more
general population. It is not possible to predict the outcomes of clinical trials so studies must be
designed to detect even the smallest effect size hence the reason for a homogenous study group.
Having better understanding of TFTs and its impact on disease trajectories will allow for more
precise adaptive or enrichment study designs. In order to do this, we must have sufficient
understanding of the how clinical outcomes such as the TFTs respond in the natural progression
of the disease.
We have seen in the last few years that FDA approval does not result in access to
treatment. Clinical endpoints become an important discussion point as key stakeholders shift
roles within drug development, approval and post market access. These gate keepers in treatment
access may shift from FDA approval to insurers who will approve/deny payment for treatments
based on the seminal study’s primary/secondary endpoint. Study trials go through rigorous
standardization of training to ensure that tests are administered and assessed in a consistent
manner to reduce the variability of the clinical endpoint. We know that an increase in variability
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of a clinical outcome leads to decrease sensitivity to detect change. When thinking of clinical
endpoints, there are multiple stakeholders that must be considered from the design of the trial to
the translation and access into the clinic. Stakeholders include the patients and clinicians who
ultimately have to administer these outcomes and justify the need for the treatment. Before
approval, researchers play a significant role in the clinical endpoints that are chosen for trials
which are mostly influenced by established psychometric soundness of the outcomes and its use
in understanding in the natural history of the disease. Fortunately for DMD, there are well
established easily administered TFTs that are consistently used in the clinic and trials.254 Our
study data contributes to the confidence of the data and addresses the gap to link clinical
significance to these TFTs so that clinicians could make timely recommendations for braces,
equipment and supports for families as they navigate the evolving progressive nature of DMD in
an era of promising therapeutic trial options.
Future developments needed in this area of contracture management and TFTs include
investigation of possible genetic factors that may predispose individuals to contracture
development. To better understand the clinical significance of loss of function, we also need to
understand patients and caregiver’s perception of clinical significance based on a level change on
the Vignos scale and its relation to quality of life. Currently, clinicians use this scale to describe
losses in function based on ability to negotiate stairs, walk, get up from the chair. These losses
allow clinicians to make changes and recommendations to IEPs, bracing and equipment which
will ultimately impact families. However, that assumption should not be made and we need to
understand from families if these changes are impactful to their lives. Lastly, since the data
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regarding stretching and night-time orthosis for contracture management is insufficient, we
would need a randomized control trial to determine the effectiveness of these treatments to
prevent or slow the progression of contractures in boys with DMD. In doing so, we need better
methods to assess not only joint ROM but physiological changes in the muscle or tendon that
may occur from stretching. Having good measures to assess possible musculotendinous changes
from different stretching regiments maybe key in better understanding the mechanisms impacted
by conservative stretch management in DMD.
In summary, the results of this study provided the first insight on contracture
development in boys with DMD in the GC era and established better understanding of its
contribution to TFTs which provides more confidence in its continued use in clinics and trials to
guide decision making.
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